<SEC-DOCUMENT>0001493152-23-018456.txt : 20230522
<SEC-HEADER>0001493152-23-018456.hdr.sgml : 20230522
<ACCEPTANCE-DATETIME>20230522083020
ACCESSION NUMBER:		0001493152-23-018456
CONFORMED SUBMISSION TYPE:	8-K
PUBLIC DOCUMENT COUNT:		19
CONFORMED PERIOD OF REPORT:	20230518
ITEM INFORMATION:		Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers: Compensatory Arrangements of Certain Officers
ITEM INFORMATION:		Regulation FD Disclosure
ITEM INFORMATION:		Financial Statements and Exhibits
FILED AS OF DATE:		20230522
DATE AS OF CHANGE:		20230522

FILER:

	COMPANY DATA:	
		COMPANY CONFORMED NAME:			Microbot Medical Inc.
		CENTRAL INDEX KEY:			0000883975
		STANDARD INDUSTRIAL CLASSIFICATION:	BIOLOGICAL PRODUCTS (NO DIAGNOSTIC SUBSTANCES) [2836]
		IRS NUMBER:				943078125
		STATE OF INCORPORATION:			DE
		FISCAL YEAR END:			1231

	FILING VALUES:
		FORM TYPE:		8-K
		SEC ACT:		1934 Act
		SEC FILE NUMBER:	000-19871
		FILM NUMBER:		23942513

	BUSINESS ADDRESS:	
		STREET 1:		25 RECREATION PARK DR SUITE 108
		CITY:			HINGHAM
		STATE:			MA
		ZIP:			02043
		BUSINESS PHONE:		908-938-5561

	MAIL ADDRESS:	
		STREET 1:		25 RECREATION PARK DR SUITE 108
		CITY:			HINGHAM
		STATE:			MA
		ZIP:			02043

	FORMER COMPANY:	
		FORMER CONFORMED NAME:	STEMCELLS INC
		DATE OF NAME CHANGE:	20000524

	FORMER COMPANY:	
		FORMER CONFORMED NAME:	CYTOTHERAPEUTICS INC/DE
		DATE OF NAME CHANGE:	19930328
</SEC-HEADER>
<DOCUMENT>
<TYPE>8-K
<SEQUENCE>1
<FILENAME>form8-k.htm
<TEXT>
<XBRL>
<?xml version="1.0" encoding="utf-8"?>
<html xmlns="http://www.w3.org/1999/xhtml" xmlns:xs="http://www.w3.org/2001/XMLSchema-instance" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:xbrli="http://www.xbrl.org/2003/instance" xmlns:xbrldi="http://xbrl.org/2006/xbrldi" xmlns:xbrldt="http://xbrl.org/2005/xbrldt" xmlns:iso4217="http://www.xbrl.org/2003/iso4217" xmlns:ix="http://www.xbrl.org/2013/inlineXBRL" xmlns:ixt="http://www.xbrl.org/inlineXBRL/transformation/2015-02-26" xmlns:ixt-sec="http://www.sec.gov/inlineXBRL/transformation/2015-08-31" xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:dei="http://xbrl.sec.gov/dei/2022" xmlns:ref="http://www.xbrl.org/2006/ref" xmlns:us-gaap="http://fasb.org/us-gaap/2022" xmlns:us-gaap-supplement="http://fasb.org/us-gaap-sup/2022q3" xmlns:srt-supplement="http://fasb.org/srt-sup/2022q3" xmlns:us-roles="http://fasb.org/us-roles/2022" xmlns:country="http://xbrl.sec.gov/country/2022" xmlns:srt="http://fasb.org/srt/2022" xmlns:MBOT="http://microbotmedical.com/20230518">
<head>
     <title></title>
<meta http-equiv="Content-Type" content="text/html" />
</head>
<!-- Field: Set; Name: xdx; ID: xdx_02B_US%2DGAAP%2D2022 -->
<!-- Field: Set; Name: xdx; ID: xdx_03C_MBOT_microbotmedical.com_20230518 -->
<!-- Field: Set; Name: xdx; ID: xdx_04C_20230518_20230518 -->
<!-- Field: Set; Name: xdx; ID: xdx_050_edei%2D%2DEntityCentralIndexKey_0000883975 -->
<!-- Field: Set; Name: xdx; ID: xdx_059_edei%2D%2DAmendmentFlag_false -->
<!-- Field: Set; Name: xdx; ID: xdx_06B_USD_1_iso4217%2D%2DUSD -->
<!-- Field: Set; Name: xdx; ID: xdx_062_Shares_2_xbrli%2D%2Dshares -->
<!-- Field: Set; Name: xdx; ID: xdx_06D_USDPShares_3_iso4217%2D%2DUSD_xbrli%2D%2Dshares -->
<body style="font: 10pt Times New Roman, Times, Serif">
<div style="display: none">
<ix:header>
 <ix:hidden>
  <ix:nonNumeric contextRef="From2023-05-18to2023-05-18" name="dei:EntityCentralIndexKey">0000883975</ix:nonNumeric>
  <ix:nonNumeric contextRef="From2023-05-18to2023-05-18" name="dei:AmendmentFlag">false</ix:nonNumeric>
  </ix:hidden>
 <ix:references>
  <link:schemaRef xlink:href="mbot-20230518.xsd" xlink:type="simple" />
  </ix:references>
 <ix:resources>
    <xbrli:context id="From2023-05-18to2023-05-18">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0000883975</xbrli:identifier>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2023-05-18</xbrli:startDate>
        <xbrli:endDate>2023-05-18</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:unit id="USD">
      <xbrli:measure>iso4217:USD</xbrli:measure>
    </xbrli:unit>
    <xbrli:unit id="Shares">
      <xbrli:measure>xbrli:shares</xbrli:measure>
    </xbrli:unit>
    <xbrli:unit id="USDPShares">
      <xbrli:divide>
        <xbrli:unitNumerator>
          <xbrli:measure>iso4217:USD</xbrli:measure>
        </xbrli:unitNumerator>
        <xbrli:unitDenominator>
          <xbrli:measure>xbrli:shares</xbrli:measure>
        </xbrli:unitDenominator>
      </xbrli:divide>
    </xbrli:unit>
  </ix:resources>
 </ix:header>
</div>


<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>&#160;</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: center"></p>

<!-- Field: Rule-Page --><div style="margin-top: 0pt; margin-bottom: 0pt; width: 100%"><div style="border-top: Black 4pt solid; border-bottom: Black 1.5pt solid; font-size: 1pt">&#160;</div></div><!-- Field: /Rule-Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>&#160;</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 18pt"><b>UNITED
STATES</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 18pt"><b>SECURITIES
AND EXCHANGE COMMISSION</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 12pt"><b>Washington,
D.C. 20549</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 18pt"><b>FORM
<span id="xdx_905_edei--DocumentType_c20230518__20230518_zNmmFrBN4oTa"><ix:nonNumeric contextRef="From2023-05-18to2023-05-18" name="dei:DocumentType">8-K</ix:nonNumeric></span></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>CURRENT
REPORT</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Pursuant
to Section 13 or 15(d)</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>of
the Securities Exchange Act of 1934</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Date
of Report (Date of earliest event reported): <span id="xdx_90D_edei--DocumentPeriodEndDate_c20230518__20230518_z71Lr9QrLNr8"><ix:nonNumeric contextRef="From2023-05-18to2023-05-18" format="ixt:datemonthdayyearen" name="dei:DocumentPeriodEndDate">May 18, 2023</ix:nonNumeric></span></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 18pt"><b><span id="xdx_907_edei--EntityRegistrantName_c20230518__20230518_zf2QduK7Y7ih"><ix:nonNumeric contextRef="From2023-05-18to2023-05-18" name="dei:EntityRegistrantName">MICROBOT
MEDICAL INC.</ix:nonNumeric></span></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>(Exact
name of registrant as specified in its charter)</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<table cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; width: 32%; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><span id="xdx_90C_edei--EntityIncorporationStateCountryCode_c20230518__20230518_zO9wGoCQ0wJ7"><ix:nonNumeric contextRef="From2023-05-18to2023-05-18" format="ixt-sec:stateprovnameen" name="dei:EntityIncorporationStateCountryCode">Delaware</ix:nonNumeric></span></b></span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; width: 2%; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; width: 32%; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><span id="xdx_90E_edei--EntityFileNumber_c20230518__20230518_zk9IWqRykzYc"><ix:nonNumeric contextRef="From2023-05-18to2023-05-18" name="dei:EntityFileNumber">000-19871</ix:nonNumeric></span></b></span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; width: 2%; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; width: 32%; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><span id="xdx_903_edei--EntityTaxIdentificationNumber_c20230518__20230518_zqbIvjMKxAHk"><ix:nonNumeric contextRef="From2023-05-18to2023-05-18" name="dei:EntityTaxIdentificationNumber">94-3078125</ix:nonNumeric></span></b></span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>(State
    or other jurisdiction</b></span></p>
    <p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>of
    incorporation)</b></span></p></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>(Commission</b></span></p>
    <p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>File
    Number)</b></span></p></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>(IRS
    Employer</b></span></p>
    <p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Identification
    No.)</b></span></p></td></tr>
  </table>
<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><span id="xdx_90A_edei--EntityAddressAddressLine1_c20230518__20230518_zAVGlieJct81"><ix:nonNumeric contextRef="From2023-05-18to2023-05-18" name="dei:EntityAddressAddressLine1">25
Recreation Park Drive</ix:nonNumeric></span>, <span id="xdx_902_edei--EntityAddressAddressLine2_c20230518__20230518_zBp0PPWYl1Cl"><ix:nonNumeric contextRef="From2023-05-18to2023-05-18" name="dei:EntityAddressAddressLine2">Unit 108</ix:nonNumeric></span></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><span id="xdx_90A_edei--EntityAddressCityOrTown_c20230518__20230518_znBd7zAvb4P4"><ix:nonNumeric contextRef="From2023-05-18to2023-05-18" name="dei:EntityAddressCityOrTown">Hingham</ix:nonNumeric></span>,
<span id="xdx_90A_edei--EntityAddressStateOrProvince_c20230518__20230518_zLgnk5b6ALlk"><ix:nonNumeric contextRef="From2023-05-18to2023-05-18" format="ixt-sec:stateprovnameen" name="dei:EntityAddressStateOrProvince">Massachusetts</ix:nonNumeric></span> <span id="xdx_901_edei--EntityAddressPostalZipCode_c20230518__20230518_zSBZOfw3Xjii"><ix:nonNumeric contextRef="From2023-05-18to2023-05-18" name="dei:EntityAddressPostalZipCode">02043</ix:nonNumeric></span></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>(Address
of Principal Executive Offices) (Zip Code)</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Registrant&#8217;s
telephone number, including area code: <span id="xdx_904_edei--CityAreaCode_c20230518__20230518_zplmnJ6YkZu4"><ix:nonNumeric contextRef="From2023-05-18to2023-05-18" name="dei:CityAreaCode">(781)</ix:nonNumeric></span> <span id="xdx_908_edei--LocalPhoneNumber_c20230518__20230518_zCQsdGYcgDJg"><ix:nonNumeric contextRef="From2023-05-18to2023-05-18" name="dei:LocalPhoneNumber">875-3605</ix:nonNumeric></span></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>(Former
Name or Former Address, if Changed Since Last Report)</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Check
the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under
any of the following provisions:</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<table cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%">
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span id="xdx_90D_edei--WrittenCommunications_c20230518__20230518_ztA3sZHiKqIg"><ix:nonNumeric contextRef="From2023-05-18to2023-05-18" format="ixt:booleanfalse" name="dei:WrittenCommunications">&#9744;</ix:nonNumeric></span></span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Written communications
    pursuant to Rule 425 under the Securities Act (17 CFR 230.425)</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span id="xdx_902_edei--SolicitingMaterial_c20230518__20230518_zilR8KP325nd"><ix:nonNumeric contextRef="From2023-05-18to2023-05-18" format="ixt:booleanfalse" name="dei:SolicitingMaterial">&#9744;</ix:nonNumeric></span></span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Soliciting material pursuant
    to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span id="xdx_90F_edei--PreCommencementTenderOffer_c20230518__20230518_zdHblQc2qaga"><ix:nonNumeric contextRef="From2023-05-18to2023-05-18" format="ixt:booleanfalse" name="dei:PreCommencementTenderOffer">&#9744;</ix:nonNumeric></span></span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Pre-commencement communications
    pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span id="xdx_907_edei--PreCommencementIssuerTenderOffer_c20230518__20230518_zUGx0EMhUW7a"><ix:nonNumeric contextRef="From2023-05-18to2023-05-18" format="ixt:booleanfalse" name="dei:PreCommencementIssuerTenderOffer">&#9744;</ix:nonNumeric></span></span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Pre-commencement communications
    pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))</span></td></tr>
  </table>
<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Securities
registered pursuant to Section 12(b) of the Act:</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<table cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom">
    <td style="border-bottom: black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; width: 40%; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Title
    of each class</b></span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; width: 2%"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="border-bottom: black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; width: 18%; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Trading
    Symbol(s)</b></span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; width: 2%"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="border-bottom: black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; width: 38%; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Name
    of each exchange on which registered</b></span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span id="xdx_90F_edei--Security12bTitle_c20230518__20230518_zOtXhYm7BqF4"><ix:nonNumeric contextRef="From2023-05-18to2023-05-18" name="dei:Security12bTitle">Common Stock, $0.01 par
    value</ix:nonNumeric></span></span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span id="xdx_909_edei--TradingSymbol_c20230518__20230518_zvWQbQUzJmEh"><ix:nonNumeric contextRef="From2023-05-18to2023-05-18" name="dei:TradingSymbol">MBOT</ix:nonNumeric></span></span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span><span id="xdx_907_edei--SecurityExchangeName_c20230518__20230518_zR7Vy5h5oEzf"><ix:nonNumeric contextRef="From2023-05-18to2023-05-18" format="ixt-sec:exchnameen" name="dei:SecurityExchangeName">NASDAQ</ix:nonNumeric></span> Capital Market</span></span></td></tr>
  </table>
<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: center; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Indicate
by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (17 CFR &#167;230.405)
or Rule 12b-2 of the Securities Exchange Act of 1934 (17 CFR &#167;240.12b-2).</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Emerging
Growth Company <span id="xdx_907_edei--EntityEmergingGrowthCompany_c20230518__20230518_zsz1AavwtIPc"><ix:nonNumeric contextRef="From2023-05-18to2023-05-18" format="ixt:booleanfalse" name="dei:EntityEmergingGrowthCompany">&#9744;</ix:nonNumeric></span></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">If
an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying
with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act.&#160;&#9744;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>&#160;</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b></b></span></p>

<!-- Field: Rule-Page --><div style="margin-top: 0pt; margin-bottom: 0pt; width: 100%"><div style="border-top: Black 1.5pt solid; border-bottom: Black 4pt solid; font-size: 1pt">&#160;</div></div><!-- Field: /Rule-Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>&#160;</b></span></p>


<!-- Field: Page; Sequence: 1 -->
    <div style="border-bottom: Black 1.5pt solid; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="width: 100%">&#160;</td></tr></table></div>
    <div style="break-before: page; margin-top: 6pt"><p style="margin: 0pt">&#160;</p></div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>&#160;</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Item
5.02 Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Offi cers; Compensatory Arrangements of
Certain Officers.</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">On
May 18, 2023, but effective as of May 15, 2023, Microbot Medical Inc. (the &#8220;Company&#8221;) entered into a series of agreements
with certain of its executive officers, all in relation to the Company&#8217;s previously announced cost restructuring plan pursuant
to which, among other things, certain executive officers agreed to a reduction of 30-40% of base salary, as follows (collectively, the
&#8220;Employment Agreement Addendums&#8221;):</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; margin-top: 0; margin-bottom: 0"><tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in"></td><td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><i>Rachel
                                            Vaknin, CFO</i>. Pursuant to an Addendum to Employment Agreement, Ms. Vaknin&#8217;s gross
                                            monthly salary shall be decreased to a gross amount of NIS 35,000. Social and fringe benefits
                                            due to Ms. Vaknin shall be calculated based upon the updated salary, excluding sick days
                                            and vacation days which will continue to be accumulated per her existing Agreement. Notwithstanding
                                            the foregoing, in the event of termination of Ms. Vaknin&#8217;s employment, either by the
                                            Company or by Ms. Vaknin, the redemption of accrued vacation days and the payment of prior
                                            notice period shall be calculated based on Ms. Vaknin&#8217;s salary prior to May 15, 2023.</span></td></tr>
<tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<td style="font: 10pt Times New Roman, Times, Serif">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: justify">&#160;</td></tr>
<tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in"></td><td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><i>Simon
                                            Sharon, CTO and General Manager</i>. Pursuant to an Addendum to Employment Agreement, Mr.
                                            Sharon&#8217;s gross monthly salary shall be decreased to a gross amount of NIS 44,496. Social
                                            and fringe benefits due to Mr. Sharon shall be calculated based upon the updated salary,
                                            excluding sick days and vacation days which will continue to be accumulated per his existing
                                            Employment Agreement. Notwithstanding the foregoing, in the event of termination of Mr. Sharon&#8217;s
                                            employment, either by the Company or by Mr. Sharon, the redemption of accrued vacation days
                                            and the payment of prior notice period shall be calculated based on Mr. Sharon&#8217;s salary
                                            prior to May 15, 2023.</span></td></tr>
<tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<td style="font: 10pt Times New Roman, Times, Serif">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: justify">&#160;</td></tr>
<tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in"></td><td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><i>Eyal
                                            Morag, CMO</i>. Pursuant to an Addendum to Employment Agreement, Dr. Morag&#8217;s gross
                                            monthly salary shall be decreased to a gross amount of NIS 49,440. Social and fringe benefits
                                            due to Dr. Morag shall be calculated based upon the updated salary, excluding sick days and
                                            vacation days which will continue to be accumulated per his existing Employment Agreement.
                                            Notwithstanding the foregoing, in the event of termination of Dr. Morag&#8217;s employment,
                                            either by the Company or by Dr. Morag, the redemption of accrued vacation days and the payment
                                            of prior notice period shall be calculated based on Dr. Morag&#8217;s salary prior to May
                                            15, 2023. Pursuant to a separate Addendum to Employment Agreement, the advance notice period
                                            upon termination of Dr. Morag&#8217;s Employment Agreement shall be shortened to ninety days.</span></td></tr></table>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0.5in; text-align: justify; text-indent: -0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
foregoing summaries of the Employment Agreement Addendums do not purport to be complete and are subject to, and qualified in their entirety
by, such documents attached as Exhibits 10.1, 10.2, 10.3 and 10.4, respectively, to this Current Report on Form 8-K, which are incorporated
herein by reference.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Item
7.01 Regulation FD Disclosure.</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">On
May 22, 2023, the Company issued a press release announcing that a team of six leading European interventional radiologists used the
LIBERTY<sup>&#174;</sup> Surgical Robotic System and achieved a 100% success rate in an extensive pre-clinical animal study, held at a
leading European-based research lab. The team of radiologists utilized the system and performed a total of 48 catheterizations to pre-determined
vascular targets including distal branches of hepatic, gastric, splenic, mesenteric, renal, and hypogastric arteries.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
press release, which is furnished as Exhibit 99.1 to this Current Report on Form 8-K, is incorporated herein by reference. The information
in this Item 7.01 and Exhibit 99.1 is being furnished and shall not be deemed to be &#8220;filed&#8221; for the purposes of Section 18
of the Securities Exchange Act of 1934, as amended, or otherwise subject to the liabilities of that section. This report will not be
deemed an admission as to the materiality of any information in this Item 7.01 or Exhibit 99.1.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Item
9.01. Financial Statements and Exhibits.</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>(d)
Exhibits</i></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>&#160;</i></b></span></p>

<table cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom">
    <td style="border-bottom: black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; white-space: nowrap; width: 0.75in"><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Exhibit</b></span></p>
    <p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Number</b></span></p></td>
    <td style="font: 10pt Times New Roman, Times, Serif; width: 0.1in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="border-bottom: black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; white-space: nowrap"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Description</b></span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom">
    <td style="font: 10pt Times New Roman, Times, Serif; white-space: nowrap"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; white-space: nowrap"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif">
    <td style="font: 10pt Times New Roman, Times, Serif; white-space: nowrap; vertical-align: top"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">10.1</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: top"><a href="ex10-1.htm"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Addendum to Employment Agreement with Rachel Vaknin</span></a></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif">
    <td style="font: 10pt Times New Roman, Times, Serif; white-space: nowrap; vertical-align: top"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">10.2</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: top"><a href="ex10-2.htm"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Addendum to Employment Agreement with Simon Sharon</span></a></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif">
    <td style="font: 10pt Times New Roman, Times, Serif; white-space: nowrap; vertical-align: top"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">10.3</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: top"><a href="ex10-3.htm"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Addendum to Employment Agreement with Eyal Morag</span></a></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif">
    <td style="font: 10pt Times New Roman, Times, Serif; white-space: nowrap; vertical-align: top"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">10.4</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: top"><a href="ex10-4.htm"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Addendum to Employment Agreement with Eyal Morag</span></a></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif">
    <td style="font: 10pt Times New Roman, Times, Serif; white-space: nowrap; vertical-align: top"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">99.1</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: top"><a href="ex99-1.htm"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Press Release dated May 22, 2023</span></a></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif">
    <td style="font: 10pt Times New Roman, Times, Serif; white-space: nowrap; vertical-align: top"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">104</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: top"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Cover Page Interactive
    Data File (embedded within the Inline XBRL document)</span></td></tr>
  </table>
<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>&#160;</b></span></p>


<!-- Field: Page; Sequence: 2 -->
    <div style="border-bottom: Black 1.5pt solid; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="width: 100%">&#160;</td></tr></table></div>
    <div style="break-before: page; margin-top: 6pt"><p style="margin: 0pt">&#160;</p></div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>&#160;</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>SIGNATURES</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Pursuant
to the requirements of the Securities Exchange Act of 1934, the Registrant has duly caused this report to be signed on its behalf by
the undersigned thereunto duly authorized.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<table cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td colspan="2" style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>MICROBOT MEDICAL INC.</b></span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td colspan="2" style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; width: 50%"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; width: 5%"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">By:</span></td>
    <td style="border-bottom: black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; width: 45%"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><i>/s/
    Harel Gadot</i></span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Name: </span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Harel Gadot</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Title:</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Chief Executive Officer, President and Chairman</span></td></tr>
  </table>
<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Date:
May 22, 2023</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>


<!-- Field: Page; Sequence: 3; Options: Last -->
    <div style="border-bottom: Black 1.5pt solid; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="width: 100%">&#160;</td></tr></table></div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

</body>
</html>
<!-- Field: Set; Name: xdx; ID: xdx_08B_extensions -->
<!-- eJxFjV0KwjAQhE/QOyx5Fk0jovTRokWsIkXE12hXCbbZskn9OZK3NLaIy8KyzHwzQgxERktTIcNxXuSwx7qptEco8IKM9ozBka7WCYRb4NU4z9r67v2BKQUGAzMZxrNTEDrr3TgsE5CTkYpHagxymigJu42IvnpK9mJKtN7oCrQtYcfUsEGv+dUn7PWTLNWvruqA7AzZBOKh7OU3KBkr2NJdP4hvDvI8FdGgm0hkTG3zrWmdpxoWFdahy/Xof6MPGiJJTA== -->
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-10.1
<SEQUENCE>2
<FILENAME>ex10-1.htm
<TEXT>
<HTML>
<HEAD>
     <TITLE></TITLE>
</HEAD>
<BODY STYLE="font: 10pt Times New Roman, Times, Serif">

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Exhibit
10.1</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><IMG SRC="ex10-3_001.jpg" ALT="" STYLE="height: 67px; width: 175px"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>&nbsp;</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B><U>ADDENDUM
TO EMPLOYMENT AGREEMENT</U></B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">made
and entered into as of May 15, 2023</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">by
and between</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0in; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Microbot
Medical Ltd.</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0in; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Registration
no. 514519412</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0in; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">of
6 Hayozma Street, Yokneam Illit, Israel</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0in; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(the
&ldquo;<B>Company</B>&rdquo;)</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0in; text-align: right; text-indent: 0.45in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><U>of
the first part</U></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0in; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">and</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0in; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0in; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Rachel
Vaknin</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0in; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Israeli
I.D no. 35883685</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0in; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">of
Israel</FONT></P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 50%"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(the
    &ldquo;<B>Employee</B>&rdquo;)</FONT></TD>
    <TD STYLE="text-align: right; font: 10pt Times New Roman, Times, Serif; width: 50%"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><U>of
the second part</U></FONT></TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 117pt; text-align: justify; text-indent: -63pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>&nbsp;</B></FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" BORDER="0" STYLE="width: 100%; margin-top: 0pt; margin-bottom: 0pt; font: 10pt Times New Roman, Times, Serif">
<TR STYLE="vertical-align: top">
  <TD STYLE="text-align: justify; padding-left: 0pt; text-indent: 0pt; width: 0.75in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>WHEREAS</B>, </FONT></TD>
  <TD STYLE="text-align: justify; padding-left: 0pt; text-indent: 0pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">the Employee is employed by the Company in accordance with
that certain employment agreement dated on November 22, 2021, and any addendum thereto (the <B>&ldquo;Employment Agreement&rdquo;);</B></FONT></TD></TR>

<TR STYLE="vertical-align: top">
  <TD STYLE="text-align: justify; padding-left: 0pt; text-indent: 0pt">&nbsp;</TD>
  <TD STYLE="text-align: justify; padding-left: 0pt; text-indent: 0pt">&nbsp;</TD></TR>
<TR STYLE="vertical-align: top">
  <TD STYLE="text-align: justify; padding-left: 0pt; text-indent: 0pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>WHEREAS, </B></FONT></TD>
  <TD STYLE="text-align: justify; padding-left: 0pt; text-indent: 0pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">due to the Company&rsquo;s financial situation and reductions
as a result thereof, the Company and the Employee have agreed to amend certain term of the Employee&rsquo;s Employment Agreement effective
as of May 15, 2023 (the <B>&ldquo;Amendment Date&rdquo;), </B>and wish to set forth in writing said understanding;</FONT></TD></TR>
</TABLE>


<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>NOW,
THEREFORE, </B>the Parties hereby agree, declare and covenant as follows:</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">1.
<U>Salary</U></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" BORDER="0" STYLE="width: 100%; margin-top: 0pt; margin-bottom: 0pt; font: 10pt Times New Roman, Times, Serif">
<TR STYLE="vertical-align: top">
  <TD STYLE="text-align: right; padding-left: 0pt; text-indent: 0pt; width: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">1.1. </FONT></TD>
    <TD STYLE="width: 0.1in">&nbsp;</TD>
  <TD STYLE="text-align: justify; padding-left: 0pt; text-indent: 0pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">As of the Amendment Date, the Employee&rsquo;s gross monthly
Salary shall be decreased to a gross amount of NIS 35,000, to be divided as follows:</FONT></TD></TR>

<TR STYLE="vertical-align: top">
  <TD STYLE="text-align: right; padding-left: 0pt; text-indent: 0pt">&nbsp;</TD>
    <TD>&nbsp;</TD>
  <TD STYLE="text-align: justify; padding-left: 0pt; text-indent: 0pt">&nbsp;</TD></TR>
<TR STYLE="vertical-align: top">
  <TD STYLE="text-align: right; padding-left: 0pt; text-indent: 0pt">&nbsp;</TD>
    <TD>&nbsp;</TD>
  <TD STYLE="text-align: justify; padding-left: 0pt; text-indent: 0pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">a. Base Salary in the amount of MS 28,000 (gross) per month;
and</FONT></TD></TR>

<TR STYLE="vertical-align: top">
  <TD STYLE="text-align: right; padding-left: 0pt; text-indent: 0pt">&nbsp;</TD>
    <TD>&nbsp;</TD>
  <TD STYLE="text-align: justify; padding-left: 0pt; text-indent: 0pt">&nbsp;</TD></TR>
<TR STYLE="vertical-align: top">
  <TD STYLE="text-align: right; padding-left: 0pt; text-indent: 0pt">&nbsp;</TD>
    <TD>&nbsp;</TD>
  <TD STYLE="text-align: justify; padding-left: 0pt; text-indent: 0pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">b. Global Compensation in the amount of NIS 7,000 (gross) per
month.</FONT></TD></TR>

<TR STYLE="vertical-align: top">
  <TD STYLE="text-align: right; padding-left: 0pt; text-indent: 0pt">&nbsp;</TD>
    <TD>&nbsp;</TD>
  <TD STYLE="text-align: justify; padding-left: 0pt; text-indent: 0pt">&nbsp;</TD></TR>
<TR STYLE="vertical-align: top">
  <TD STYLE="text-align: right; padding-left: 0pt; text-indent: 0pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">1.2. </FONT></TD>
    <TD>&nbsp;</TD>
  <TD STYLE="text-align: justify; padding-left: 0pt; text-indent: 0pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Social and fringe benefits due to the Employee according to
the Employment Agreement shall be calculated based upon the updated Salary, excluding sick days and vacation days which will continue
to be accumulated per to Employee&rsquo;s Employment Agreement dated November 22, 2021.</FONT></TD></TR>

<TR STYLE="vertical-align: top">
  <TD STYLE="text-align: right; padding-left: 0pt; text-indent: 0pt">&nbsp;</TD>
    <TD>&nbsp;</TD>
  <TD STYLE="text-align: justify; padding-left: 0pt; text-indent: 0pt">&nbsp;</TD></TR>
<TR STYLE="vertical-align: top">
  <TD STYLE="text-align: right; padding-left: 0pt; text-indent: 0pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">1.3. </FONT></TD>
    <TD>&nbsp;</TD>
  <TD STYLE="text-align: justify; padding-left: 0pt; text-indent: 0pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Notwithstanding the foregoing, in the event of termination
of the Employee&rsquo;s employment, either by the company or by the employee, the redemption of accrued vacation days and the payment
of prior notice period shall be calculated based on the Employee&rsquo;s salary prior to the Amendment Date.</FONT></TD></TR>
</TABLE>


<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1.4in; text-align: justify; text-indent: -0.3in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">2.
<U>Miscellaneous</U></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0.85in; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" BORDER="0" STYLE="width: 100%; margin-top: 0pt; margin-bottom: 0pt; font: 10pt Times New Roman, Times, Serif">
<TR STYLE="vertical-align: top">
  <TD STYLE="text-align: right; padding-left: 0pt; text-indent: 0pt; width: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">2.1. </FONT></TD>
    <TD STYLE="width: 0.1in">&nbsp;</TD>
  <TD STYLE="text-align: justify; padding-left: 0pt; text-indent: 0pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Capitalized terms used herein, unless otherwise defined, shall
have the meanings ascribed to them in the Employment Agreement.</FONT></TD></TR>

<TR STYLE="vertical-align: top">
  <TD STYLE="text-align: right; padding-left: 0pt; text-indent: 0pt">&nbsp;</TD>
    <TD>&nbsp;</TD>
  <TD STYLE="text-align: justify; padding-left: 0pt; text-indent: 0pt">&nbsp;</TD></TR>
<TR STYLE="vertical-align: top">
  <TD STYLE="text-align: right; padding-left: 0pt; text-indent: 0pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">2.2. </FONT></TD>
    <TD>&nbsp;</TD>
  <TD STYLE="text-align: justify; padding-left: 0pt; text-indent: 0pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">This Addendum contains the entire agreement between the parties
hereto with respect to the subject matter hereof, supersedes and cancels all prior agreements, arrangements and understandings, written
or oral, relating to the subject matter hereof, if any. In any event of contradiction between the provisions of this Addendum and any
prior agreement, whether written or oral, the provisions of this Addendum shall prevail.</FONT></TD></TR>
</TABLE>


<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Microbot
Medical Ltd., 6 Hayozma St, Yokneam Illit, 2069024. P.O.B 242, Israel</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Office: +972-4-8200710 Fax: +972-4-8200712</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B><U>www.microbotmedical.com</U></B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 3.4in; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>&nbsp;</B></FONT></P>


<!-- Field: Page; Sequence: 1 -->
    <DIV STYLE="margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><IMG SRC="ex10-3_001.jpg" ALT="" STYLE="height: 67px; width: 175px"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" BORDER="0" STYLE="width: 100%; margin-top: 0pt; margin-bottom: 0pt; font: 10pt Times New Roman, Times, Serif">
<TR STYLE="vertical-align: top">
  <TD STYLE="text-align: right; padding-left: 0pt; text-indent: 0pt; width: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">2.3. </FONT></TD>
    <TD STYLE="width: 0.1in">&nbsp;</TD>
  <TD STYLE="text-align: justify; padding-left: 0pt; text-indent: 0pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">This Addendum may be amended, modified, superseded, canceled,
renewed or extended, and the terms and covenants hereof may be waived, only by a written instrument executed by both parties. A waiver
of any term or condition of this Addendum may be effected only by a written instrument executed by the party waiving compliance. The
failure of any party, at any time or times, to require performance of any provision of this Addendum shall in no manner affect the right
of such party, at a later time, to enforce the same. No waiver by any party of the breach of any term or covenant, whether by conduct
or otherwise, in any one or more instances, shall be deemed to be, or construed as, a further or continuing waiver of any breach, or
a waiver of the breach of any other term or covenant.</FONT></TD></TR>

<TR STYLE="vertical-align: top">
  <TD STYLE="text-align: right; padding-left: 0pt; text-indent: 0pt">&nbsp;</TD>
    <TD>&nbsp;</TD>
  <TD STYLE="text-align: justify; padding-left: 0pt; text-indent: 0pt">&nbsp;</TD></TR>
<TR STYLE="vertical-align: top">
  <TD STYLE="text-align: right; padding-left: 0pt; text-indent: 0pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">2.4. </FONT></TD>
    <TD>&nbsp;</TD>
  <TD STYLE="text-align: justify; padding-left: 0pt; text-indent: 0pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Except to the extent otherwise specifically modified herein
in this Addendum all of the terms and conditions of the Employment Agreement are hereby ratified, approved and confirmed and all such
terms and conditions shall remain in full force and effect.</FONT></TD></TR>
</TABLE>


<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>IN
WITNESS WHEREOF</B>, the parties execute hereunder:</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="text-align: center; border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; width: 49%"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><I>/s/
    Naama Moav</I></FONT></TD>
    <TD STYLE="text-align: center; padding-bottom: 1.5pt; font: 10pt Times New Roman, Times, Serif; width: 2%"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="text-align: center; border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; width: 49%"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><I>/s/
    Rachel Vaknin</I></FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="text-align: center; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Microbot
Medical Ltd.</B></FONT></TD>
    <TD STYLE="text-align: center; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="text-align: center; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Rachel
    Vaknin</B></FONT></TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1in; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>&nbsp;</B></FONT></P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 3%"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>By</B></FONT></TD>
    <TD STYLE="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; width: 47%"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 50%"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Microbot
Medical Ltd., 6 Hayozma St, Yokneam Illit, 2069024. P.O.B 242, Israel</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Office:
+972-4-8200710 Fax: +972-4-8200712</B></FONT></P>

<P STYLE="text-align: center; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"> <FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B><U>www.microbotmedical.com</U></B></FONT></P>



<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 2.35in; text-align: center; text-indent: -1.9in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>&nbsp;</B></FONT></P>


<!-- Field: Page; Sequence: 2; Options: Last -->
    <DIV STYLE="margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 2.35in; text-align: center; text-indent: -1.9in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

</BODY>
</HTML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-10.2
<SEQUENCE>3
<FILENAME>ex10-2.htm
<TEXT>
<HTML>
<HEAD>
     <TITLE></TITLE>
</HEAD>
<BODY STYLE="font: 10pt Times New Roman, Times, Serif">

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Exhibit
10.2</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><IMG SRC="ex10-3_001.jpg" ALT="" STYLE="height: 67px; width: 175px"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>&nbsp;</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B><U>ADDENDUM
TO EMPLOYMENT AGREEMENT</U></B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">made
and entered into as of May 15, 2023</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">by
and between</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0in; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Microbot
Medical Ltd.</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0in; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Registration
no. 514519412</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0in; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">of
6 Hayozma Street, Yokneam Illit, Israel</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0in; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(the
&ldquo;<B>Company</B>&rdquo;)</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0in; text-align: right; text-indent: 0.45in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><U>of
the first part</U></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0in; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">and</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0in; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0in; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B></B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">Simon Sharon</P>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0in; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B></B></FONT></P>

<P STYLE="text-indent: 20pt; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0in; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Israeli
I.D no. 27037753</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0in; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">of
Israel</FONT></P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 50%"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(the
    &ldquo;<B>Employee</B>&rdquo;)</FONT></TD>
    <TD STYLE="text-align: right; font: 10pt Times New Roman, Times, Serif; width: 50%"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><U>of
the second part</U></FONT></TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 117pt; text-align: justify; text-indent: -63pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>&nbsp;</B></FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" BORDER="0" STYLE="width: 100%; margin-top: 0pt; margin-bottom: 0pt; font: 10pt Times New Roman, Times, Serif">
<TR STYLE="vertical-align: top">
  <TD STYLE="text-align: justify; padding-left: 0pt; text-indent: 0pt; width: 0.75in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>WHEREAS</B>, </FONT></TD>
  <TD STYLE="text-align: justify; padding-left: 0pt; text-indent: 0pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">the Employee is employed by the Company in accordance with
that certain employment agreement dated on March 31, 2018, and any addendum thereto (the <B>&ldquo;Employment Agreement&rdquo;);</B></FONT></TD></TR>

<TR STYLE="vertical-align: top">
  <TD STYLE="text-align: justify; padding-left: 0pt; text-indent: 0pt">&nbsp;</TD>
  <TD STYLE="text-align: justify; padding-left: 0pt; text-indent: 0pt">&nbsp;</TD></TR>
<TR STYLE="vertical-align: top">
  <TD STYLE="text-align: justify; padding-left: 0pt; text-indent: 0pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>WHEREAS, </B></FONT></TD>
  <TD STYLE="text-align: justify; padding-left: 0pt; text-indent: 0pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">due to the Company&rsquo;s financial situation and reductions
as a result thereof, the Company and the Employee have agreed to amend certain term of the Employee&rsquo;s Employment Agreement effective
as of May 15, 2023 (the <B>&ldquo;Amendment Date&rdquo;), </B>and wish to set forth in writing said understanding;</FONT></TD></TR>
</TABLE>


<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>NOW,
THEREFORE, </B>the Parties hereby agree, declare and covenant as follows:</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">1.
<U>Salary</U></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" BORDER="0" STYLE="width: 100%; margin-top: 0pt; margin-bottom: 0pt; font: 10pt Times New Roman, Times, Serif">
<TR STYLE="vertical-align: top">
  <TD STYLE="text-align: right; padding-left: 0pt; text-indent: 0pt; width: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">1.1. </FONT></TD>
    <TD STYLE="width: 0.1in">&nbsp;</TD>
  <TD STYLE="text-align: justify; padding-left: 0pt; text-indent: 0pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">As of the Amendment Date, the Employee&rsquo;s gross monthly
Salary shall be decreased to a gross amount of NIS 44,496, to be divided as follows:</FONT></TD></TR>

<TR STYLE="vertical-align: top">
  <TD STYLE="text-align: right; padding-left: 0pt; text-indent: 0pt">&nbsp;</TD>
    <TD>&nbsp;</TD>
  <TD STYLE="text-align: justify; padding-left: 0pt; text-indent: 0pt">&nbsp;</TD></TR>
<TR STYLE="vertical-align: top">
  <TD STYLE="text-align: right; padding-left: 0pt; text-indent: 0pt">&nbsp;</TD>
    <TD>&nbsp;</TD>
  <TD STYLE="text-align: justify; padding-left: 0pt; text-indent: 0pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">a. Base Salary in the amount of NIS 35,596.8 (gross) per month;
and</FONT></TD></TR>

<TR STYLE="vertical-align: top">
  <TD STYLE="text-align: right; padding-left: 0pt; text-indent: 0pt">&nbsp;</TD>
    <TD>&nbsp;</TD>
  <TD STYLE="text-align: justify; padding-left: 0pt; text-indent: 0pt">&nbsp;</TD></TR>
<TR STYLE="vertical-align: top">
  <TD STYLE="text-align: right; padding-left: 0pt; text-indent: 0pt">&nbsp;</TD>
    <TD>&nbsp;</TD>
  <TD STYLE="text-align: justify; padding-left: 0pt; text-indent: 0pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">b. Global Compensation in the amount of NIS 8,899.2 (gross) per
month.</FONT></TD></TR>

<TR STYLE="vertical-align: top">
  <TD STYLE="text-align: right; padding-left: 0pt; text-indent: 0pt">&nbsp;</TD>
    <TD>&nbsp;</TD>
  <TD STYLE="text-align: justify; padding-left: 0pt; text-indent: 0pt">&nbsp;</TD></TR>
<TR STYLE="vertical-align: top">
  <TD STYLE="text-align: right; padding-left: 0pt; text-indent: 0pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">1.2. </FONT></TD>
    <TD>&nbsp;</TD>
  <TD STYLE="text-align: justify; padding-left: 0pt; text-indent: 0pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Social and fringe benefits due to the Employee according to
the Employment Agreement shall be calculated based upon the updated Salary, excluding sick days and vacation days which will continue
to be accumulated per to Employee&rsquo;s Employment Agreement dated February 18, 2020.</FONT></TD></TR>

<TR STYLE="vertical-align: top">
  <TD STYLE="text-align: right; padding-left: 0pt; text-indent: 0pt">&nbsp;</TD>
    <TD>&nbsp;</TD>
  <TD STYLE="text-align: justify; padding-left: 0pt; text-indent: 0pt">&nbsp;</TD></TR>
<TR STYLE="vertical-align: top">
  <TD STYLE="text-align: right; padding-left: 0pt; text-indent: 0pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">1.3. </FONT></TD>
    <TD>&nbsp;</TD>
  <TD STYLE="text-align: justify; padding-left: 0pt; text-indent: 0pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Notwithstanding the foregoing, in the event of termination
of the Employee&rsquo;s employment, either by the company or by the employee, the redemption of accrued vacation days and the payment
of prior notice period shall be calculated based on the Employee&rsquo;s salary prior to the Amendment Date.</FONT></TD></TR>
</TABLE>


<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1.4in; text-align: justify; text-indent: -0.3in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">2.
<U>Miscellaneous</U></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0.85in; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" BORDER="0" STYLE="width: 100%; margin-top: 0pt; margin-bottom: 0pt; font: 10pt Times New Roman, Times, Serif">
<TR STYLE="vertical-align: top">
  <TD STYLE="text-align: right; padding-left: 0pt; text-indent: 0pt; width: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">2.1. </FONT></TD>
    <TD STYLE="width: 0.1in">&nbsp;</TD>
  <TD STYLE="text-align: justify; padding-left: 0pt; text-indent: 0pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Capitalized terms used herein, unless otherwise defined, shall
have the meanings ascribed to them in the Employment Agreement.</FONT></TD></TR>

<TR STYLE="vertical-align: top">
  <TD STYLE="text-align: right; padding-left: 0pt; text-indent: 0pt">&nbsp;</TD>
    <TD>&nbsp;</TD>
  <TD STYLE="text-align: justify; padding-left: 0pt; text-indent: 0pt">&nbsp;</TD></TR>
<TR STYLE="vertical-align: top">
  <TD STYLE="text-align: right; padding-left: 0pt; text-indent: 0pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">2.2. </FONT></TD>
    <TD>&nbsp;</TD>
  <TD STYLE="text-align: justify; padding-left: 0pt; text-indent: 0pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">This Addendum contains the entire agreement between the parties
hereto with respect to the subject matter hereof, supersedes and cancels all prior agreements, arrangements and understandings, written
or oral, relating to the subject matter hereof, if any. In any event of contradiction between the provisions of this Addendum and any
prior agreement, whether written or oral, the provisions of this Addendum shall prevail.</FONT></TD></TR>
</TABLE>


<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Microbot
Medical Ltd., 6 Hayozma St, Yokneam Illit, 2069024. P.O.B 242, Israel</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Office: +972-4-8200710 Fax: +972-4-8200712</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B><U>www.microbotmedical.com</U></B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 3.4in; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>&nbsp;</B></FONT></P>


<!-- Field: Page; Sequence: 1 -->
    <DIV STYLE="margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><IMG SRC="ex10-3_001.jpg" ALT="" STYLE="height: 67px; width: 175px"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" BORDER="0" STYLE="width: 100%; margin-top: 0pt; margin-bottom: 0pt; font: 10pt Times New Roman, Times, Serif">
<TR STYLE="vertical-align: top">
  <TD STYLE="text-align: right; padding-left: 0pt; text-indent: 0pt; width: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">2.3. </FONT></TD>
    <TD STYLE="width: 0.1in">&nbsp;</TD>
  <TD STYLE="text-align: justify; padding-left: 0pt; text-indent: 0pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">This Addendum may be amended, modified, superseded, canceled,
renewed or extended, and the terms and covenants hereof may be waived, only by a written instrument executed by both parties. A waiver
of any term or condition of this Addendum may be effected only by a written instrument executed by the party waiving compliance. The
failure of any party, at any time or times, to require performance of any provision of this Addendum shall in no manner affect the right
of such party, at a later time, to enforce the same. No waiver by any party of the breach of any term or covenant, whether by conduct
or otherwise, in any one or more instances, shall be deemed to be, or construed as, a further or continuing waiver of any breach, or
a waiver of the breach of any other term or covenant.</FONT></TD></TR>

<TR STYLE="vertical-align: top">
  <TD STYLE="text-align: right; padding-left: 0pt; text-indent: 0pt">&nbsp;</TD>
    <TD>&nbsp;</TD>
  <TD STYLE="text-align: justify; padding-left: 0pt; text-indent: 0pt">&nbsp;</TD></TR>
<TR STYLE="vertical-align: top">
  <TD STYLE="text-align: right; padding-left: 0pt; text-indent: 0pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">2.4. </FONT></TD>
    <TD>&nbsp;</TD>
  <TD STYLE="text-align: justify; padding-left: 0pt; text-indent: 0pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Except to the extent otherwise specifically modified herein
in this Addendum all of the terms and conditions of the Employment Agreement are hereby ratified, approved and confirmed and all such
terms and conditions shall remain in full force and effect.</FONT></TD></TR>
</TABLE>


<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>IN
WITNESS WHEREOF</B>, the parties execute hereunder:</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="text-align: center; border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; width: 49%"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><I>/s/
    Naama Moav</I></FONT></TD>
    <TD STYLE="text-align: center; padding-bottom: 1.5pt; font: 10pt Times New Roman, Times, Serif; width: 2%"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="text-align: center; border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; width: 49%"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><I>/s/
    Simon Sharon</I></FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="text-align: center; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Microbot
Medical Ltd.</B></FONT></TD>
    <TD STYLE="text-align: center; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="text-align: center; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Simon Sharon</B></FONT></TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1in; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>&nbsp;</B></FONT></P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 3%"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>By</B></FONT></TD>
    <TD STYLE="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; width: 47%"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 50%"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Microbot
Medical Ltd., 6 Hayozma St, Yokneam Illit, 2069024. P.O.B 242, Israel</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Office:
+972-4-8200710 Fax: +972-4-8200712</B></FONT></P>

<P STYLE="text-align: center; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"> <FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B><U>www.microbotmedical.com</U></B></FONT></P>



<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 2.35in; text-align: center; text-indent: -1.9in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>&nbsp;</B></FONT></P>


<!-- Field: Page; Sequence: 2; Options: Last -->
    <DIV STYLE="margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 2.35in; text-align: center; text-indent: -1.9in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

</BODY>
</HTML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-10.3
<SEQUENCE>4
<FILENAME>ex10-3.htm
<TEXT>
<HTML>
<HEAD>
     <TITLE></TITLE>
</HEAD>
<BODY STYLE="font: 10pt Times New Roman, Times, Serif">

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Exhibit
10.3</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><IMG SRC="ex10-3_001.jpg" ALT="" STYLE="height: 67px; width: 175px"></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>&nbsp;</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B><U>ADDENDUM
TO EMPLOYMENT AGREEMENT</U></B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">made
and entered into as of May 15, 2023</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">by
and between</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0in; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Microbot
Medical Ltd.</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0in; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Registration
no. 514519412</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0in; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">of
6 Hayozma Street, Yokneam Illit, Israel</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0in; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(the
&ldquo;<B>Company</B>&rdquo;)</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0in; text-align: right; text-indent: 0.45in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><U>of
the first part</U></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0in; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">and</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0in; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 11pt/12.45pt Times New Roman, Times, Serif; text-align: left; margin-top: 12.95pt; margin-bottom: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Eyal
Morag</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0in; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Israeli
I.D no. 58830084</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0in; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">of
Israel</FONT></P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 50%"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(the
    &ldquo;<B>Employee</B>&rdquo;)</FONT></TD>
    <TD STYLE="text-align: right; font: 10pt Times New Roman, Times, Serif; width: 50%"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><U>of
the second part</U></FONT></TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 117pt; text-align: justify; text-indent: -63pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>&nbsp;</B></FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" BORDER="0" STYLE="width: 100%; margin-top: 0pt; margin-bottom: 0pt; font: 10pt Times New Roman, Times, Serif">
<TR STYLE="vertical-align: top">
  <TD STYLE="text-align: justify; padding-left: 0pt; text-indent: 0pt; width: 0.75in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>WHEREAS</B>, </FONT></TD>
  <TD STYLE="text-align: justify; padding-left: 0pt; text-indent: 0pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">the Employee is employed by the Company in accordance with
that certain employment agreement dated on February 18, 2020, and any addendum thereto (the <B>&ldquo;Employment Agreement&rdquo;);</B></FONT></TD></TR>

<TR STYLE="vertical-align: top">
  <TD STYLE="text-align: justify; padding-left: 0pt; text-indent: 0pt">&nbsp;</TD>
  <TD STYLE="text-align: justify; padding-left: 0pt; text-indent: 0pt">&nbsp;</TD></TR>
<TR STYLE="vertical-align: top">
  <TD STYLE="text-align: justify; padding-left: 0pt; text-indent: 0pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>WHEREAS, </B></FONT></TD>
  <TD STYLE="text-align: justify; padding-left: 0pt; text-indent: 0pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">due to the Company&rsquo;s financial situation and reductions
as a result thereof, the Company and the Employee have agreed to amend certain term of the Employee&rsquo;s Employment Agreement effective
as of May 15, 2023 (the <B>&ldquo;Amendment Date&rdquo;), </B>and wish to set forth in writing said understanding;</FONT></TD></TR>
</TABLE>


<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>NOW,
THEREFORE, </B>the Parties hereby agree, declare and covenant as follows:</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">1.
<U>Salary</U></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" BORDER="0" STYLE="width: 100%; margin-top: 0pt; margin-bottom: 0pt; font: 10pt Times New Roman, Times, Serif">
<TR STYLE="vertical-align: top">
  <TD STYLE="text-align: right; padding-left: 0pt; text-indent: 0pt; width: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">1.1. </FONT></TD>
    <TD STYLE="width: 0.1in">&nbsp;</TD>
  <TD STYLE="text-align: justify; padding-left: 0pt; text-indent: 0pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">As of the Amendment Date, the Employee&rsquo;s gross monthly
Salary shall be decreased to a gross amount of NIS 49,440, to be divided as follows:</FONT></TD></TR>

<TR STYLE="vertical-align: top">
  <TD STYLE="text-align: right; padding-left: 0pt; text-indent: 0pt">&nbsp;</TD>
    <TD>&nbsp;</TD>
  <TD STYLE="text-align: justify; padding-left: 0pt; text-indent: 0pt">&nbsp;</TD></TR>
<TR STYLE="vertical-align: top">
  <TD STYLE="text-align: right; padding-left: 0pt; text-indent: 0pt">&nbsp;</TD>
    <TD>&nbsp;</TD>
  <TD STYLE="text-align: justify; padding-left: 0pt; text-indent: 0pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">a. Base Salary in the amount of NIS 39,552 (gross) per month;
and</FONT></TD></TR>

<TR STYLE="vertical-align: top">
  <TD STYLE="text-align: right; padding-left: 0pt; text-indent: 0pt">&nbsp;</TD>
    <TD>&nbsp;</TD>
  <TD STYLE="text-align: justify; padding-left: 0pt; text-indent: 0pt">&nbsp;</TD></TR>
<TR STYLE="vertical-align: top">
  <TD STYLE="text-align: right; padding-left: 0pt; text-indent: 0pt">&nbsp;</TD>
    <TD>&nbsp;</TD>
  <TD STYLE="text-align: justify; padding-left: 0pt; text-indent: 0pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">b. Global Compensation in the amount of NIS 9,888 (gross) per
month.</FONT></TD></TR>

<TR STYLE="vertical-align: top">
  <TD STYLE="text-align: right; padding-left: 0pt; text-indent: 0pt">&nbsp;</TD>
    <TD>&nbsp;</TD>
  <TD STYLE="text-align: justify; padding-left: 0pt; text-indent: 0pt">&nbsp;</TD></TR>
<TR STYLE="vertical-align: top">
  <TD STYLE="text-align: right; padding-left: 0pt; text-indent: 0pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">1.2. </FONT></TD>
    <TD>&nbsp;</TD>
  <TD STYLE="text-align: justify; padding-left: 0pt; text-indent: 0pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Social and fringe benefits due to the Employee according to
the Employment Agreement shall be calculated based upon the updated Salary, excluding sick days and vacation days which will continue
to be accumulated per to Employee&rsquo;s Employment Agreement dated February 18, 2020.</FONT></TD></TR>

<TR STYLE="vertical-align: top">
  <TD STYLE="text-align: right; padding-left: 0pt; text-indent: 0pt">&nbsp;</TD>
    <TD>&nbsp;</TD>
  <TD STYLE="text-align: justify; padding-left: 0pt; text-indent: 0pt">&nbsp;</TD></TR>
<TR STYLE="vertical-align: top">
  <TD STYLE="text-align: right; padding-left: 0pt; text-indent: 0pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">1.3. </FONT></TD>
    <TD>&nbsp;</TD>
  <TD STYLE="text-align: justify; padding-left: 0pt; text-indent: 0pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Notwithstanding the foregoing, in the event of termination
of the Employee&rsquo;s employment, either by the company or by the employee, the redemption of accrued vacation days and the payment
of prior notice period shall be calculated based on the Employee&rsquo;s salary prior to the Amendment Date.</FONT></TD></TR>
</TABLE>


<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1.4in; text-align: justify; text-indent: -0.3in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">2.
<U>Miscellaneous</U></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0.85in; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" BORDER="0" STYLE="width: 100%; margin-top: 0pt; margin-bottom: 0pt; font: 10pt Times New Roman, Times, Serif">
<TR STYLE="vertical-align: top">
  <TD STYLE="text-align: right; padding-left: 0pt; text-indent: 0pt; width: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">2.1. </FONT></TD>
    <TD STYLE="width: 0.1in">&nbsp;</TD>
  <TD STYLE="text-align: justify; padding-left: 0pt; text-indent: 0pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Capitalized terms used herein, unless otherwise defined, shall
have the meanings ascribed to them in the Employment Agreement.</FONT></TD></TR>

<TR STYLE="vertical-align: top">
  <TD STYLE="text-align: right; padding-left: 0pt; text-indent: 0pt">&nbsp;</TD>
    <TD>&nbsp;</TD>
  <TD STYLE="text-align: justify; padding-left: 0pt; text-indent: 0pt">&nbsp;</TD></TR>
<TR STYLE="vertical-align: top">
  <TD STYLE="text-align: right; padding-left: 0pt; text-indent: 0pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">2.2. </FONT></TD>
    <TD>&nbsp;</TD>
  <TD STYLE="text-align: justify; padding-left: 0pt; text-indent: 0pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">This Addendum contains the entire agreement between the parties
hereto with respect to the subject matter hereof, supersedes and cancels all prior agreements, arrangements and understandings, written
or oral, relating to the subject matter hereof, if any. In any event of contradiction between the provisions of this Addendum and any
prior agreement, whether written or oral, the provisions of this Addendum shall prevail.</FONT></TD></TR>
</TABLE>


<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Microbot
Medical Ltd., 6 Hayozma St, Yokneam Illit, 2069024. P.O.B 242, Israel</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Office: +972-4-8200710 Fax: +972-4-8200712</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B><U>www.microbotmedical.com</U></B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 3.4in; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>&nbsp;</B></FONT></P>


<!-- Field: Page; Sequence: 1 -->
    <DIV STYLE="margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><IMG SRC="ex10-3_001.jpg" ALT="" STYLE="height: 67px; width: 175px"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" BORDER="0" STYLE="width: 100%; margin-top: 0pt; margin-bottom: 0pt; font: 10pt Times New Roman, Times, Serif">
<TR STYLE="vertical-align: top">
  <TD STYLE="text-align: right; padding-left: 0pt; text-indent: 0pt; width: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">2.3. </FONT></TD>
    <TD STYLE="width: 0.1in">&nbsp;</TD>
  <TD STYLE="text-align: justify; padding-left: 0pt; text-indent: 0pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">This Addendum may be amended, modified, superseded, canceled,
renewed or extended, and the terms and covenants hereof may be waived, only by a written instrument executed by both parties. A waiver
of any term or condition of this Addendum may be effected only by a written instrument executed by the party waiving compliance. The
failure of any party, at any time or times, to require performance of any provision of this Addendum shall in no manner affect the right
of such party, at a later time, to enforce the same. No waiver by any party of the breach of any term or covenant, whether by conduct
or otherwise, in any one or more instances, shall be deemed to be, or construed as, a further or continuing waiver of any breach, or
a waiver of the breach of any other term or covenant.</FONT></TD></TR>

<TR STYLE="vertical-align: top">
  <TD STYLE="text-align: right; padding-left: 0pt; text-indent: 0pt">&nbsp;</TD>
    <TD>&nbsp;</TD>
  <TD STYLE="text-align: justify; padding-left: 0pt; text-indent: 0pt">&nbsp;</TD></TR>
<TR STYLE="vertical-align: top">
  <TD STYLE="text-align: right; padding-left: 0pt; text-indent: 0pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">2.4. </FONT></TD>
    <TD>&nbsp;</TD>
  <TD STYLE="text-align: justify; padding-left: 0pt; text-indent: 0pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Except to the extent otherwise specifically modified herein
in this Addendum all of the terms and conditions of the Employment Agreement are hereby ratified, approved and confirmed and all such
terms and conditions shall remain in full force and effect.</FONT></TD></TR>
</TABLE>


<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>IN
WITNESS WHEREOF</B>, the parties execute hereunder:</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="text-align: center; border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; width: 49%"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><I>/s/
    Naama Moav</I></FONT></TD>
    <TD STYLE="text-align: center; padding-bottom: 1.5pt; font: 10pt Times New Roman, Times, Serif; width: 2%"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="text-align: center; border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; width: 49%"><I>/s/ Eyal
    Morag</I></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="text-align: center; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Microbot
Medical Ltd.</B></FONT></TD>
    <TD STYLE="text-align: center; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="text-align: center; font: 10pt Times New Roman, Times, Serif">Eyal Morag</TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1in; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>&nbsp;</B></FONT></P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 3%"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>By</B></FONT></TD>
    <TD STYLE="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; width: 47%"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 50%"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Microbot
Medical Ltd., 6 Hayozma St, Yokneam Illit, 2069024. P.O.B 242, Israel</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Office:
+972-4-8200710 Fax: +972-4-8200712</B></FONT></P>

<P STYLE="text-align: center; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"> <FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B><U>www.microbotmedical.com</U></B></FONT></P>



<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 2.35in; text-align: center; text-indent: -1.9in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>&nbsp;</B></FONT></P>


<!-- Field: Page; Sequence: 2; Options: Last -->
    <DIV STYLE="margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 2.35in; text-align: center; text-indent: -1.9in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

</BODY>
</HTML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-10.4
<SEQUENCE>5
<FILENAME>ex10-4.htm
<TEXT>
<HTML>
<HEAD>
     <TITLE></TITLE>
</HEAD>
<BODY STYLE="font: 10pt Times New Roman, Times, Serif">

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Exhibit
10.4</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><IMG SRC="ex10-3_001.jpg" ALT="" STYLE="height: 67px; width: 175px"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>&nbsp;</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B><U>ADDENDUM
TO EMPLOYMENT AGREEMENT</U></B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">made
and entered into as of May 15, 2023</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">by
and between</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0in; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Microbot
Medical Ltd.</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0in; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Registration
no. 514519412</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0in; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">of
34 (B2) Ramhal St., Acco, Israel</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0in; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(the
&ldquo;<B>Company</B>&rdquo;)</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0in; text-align: right; text-indent: 0.45in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><U>of
the first part</U></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0in; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">and</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0in; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0in; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B></B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">Dr. Eyal Morag</P>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0in; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B></B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0in; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Israeli
I.D no. 058830084</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0in; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">of
Israel</FONT></P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 50%"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(the
    &ldquo;<B>Employee</B>&rdquo;)</FONT></TD>
    <TD STYLE="text-align: right; font: 10pt Times New Roman, Times, Serif; width: 50%"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><U>of
the second part</U></FONT></TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 117pt; text-align: justify; text-indent: -63pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>&nbsp;</B></FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" BORDER="0" STYLE="width: 100%; margin-top: 0pt; margin-bottom: 0pt; font: 10pt Times New Roman, Times, Serif">
<TR STYLE="vertical-align: top">
  <TD STYLE="text-align: justify; padding-left: 0pt; text-indent: 0pt; width: 0.75in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>WHEREAS</B>, </FONT></TD>
  <TD STYLE="text-align: justify; padding-left: 0pt; text-indent: 0pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">the Employee is employed by the Company in accordance with
that certain employment agreement dated February 18, 2020, and any addendum thereto (the <B>&ldquo;Employment Agreement&rdquo;);</B></FONT></TD></TR>

<TR STYLE="vertical-align: top">
  <TD STYLE="text-align: justify; padding-left: 0pt; text-indent: 0pt">&nbsp;</TD>
  <TD STYLE="text-align: justify; padding-left: 0pt; text-indent: 0pt">&nbsp;</TD></TR>
<TR STYLE="vertical-align: top">
  <TD STYLE="text-align: justify; padding-left: 0pt; text-indent: 0pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>WHEREAS, </B></FONT></TD>
  <TD STYLE="text-align: justify; padding-left: 0pt; text-indent: 0pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">the
  Company and the Employee have agreed to amend certain terms of the Employee&rsquo;s employment, effective as of May 15, 2023 (the <B>&ldquo;Interim
  Period&rdquo;), as set forth in writing below;</B></FONT></TD></TR>
</TABLE>


<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>NOW,
THEREFORE, </B>the Parties hereby agree, declare and covenant as follows:</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">1. <U>Prior Notice of Termination</U></P>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><U></U></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" BORDER="0" STYLE="width: 100%; margin-top: 0pt; margin-bottom: 0pt; font: 10pt Times New Roman, Times, Serif">
<TR STYLE="vertical-align: top">
  <TD STYLE="text-align: right; padding-left: 0pt; text-indent: 0pt; width: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">1.1. </FONT></TD>
    <TD STYLE="width: 0.1in">&nbsp;</TD>
  <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify; padding-left: 0pt; text-indent: 0pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">During
  the Interim Period, the Advance Notice Period, in case either one of the parties decides to terminate the Employment Agreement (i.e.
  either dismissal or resignation) shall be shortened to ninety (90) days.</FONT></TD></TR>




</TABLE>


<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1.4in; text-align: justify; text-indent: -0.3in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">2.
<U>Miscellaneous</U></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0.85in; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" BORDER="0" STYLE="width: 100%; margin-top: 0pt; margin-bottom: 0pt; font: 10pt Times New Roman, Times, Serif">
<TR STYLE="vertical-align: top">
  <TD STYLE="text-align: right; padding-left: 0pt; text-indent: 0pt; width: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">2.1. </FONT></TD>
    <TD STYLE="width: 0.1in">&nbsp;</TD>
  <TD STYLE="text-align: justify; padding-left: 0pt; text-indent: 0pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Capitalized terms used herein, unless otherwise defined, shall
have the meanings ascribed to them in the Employment Agreement.</FONT></TD></TR>

<TR STYLE="vertical-align: top">
  <TD STYLE="text-align: right; padding-left: 0pt; text-indent: 0pt">&nbsp;</TD>
    <TD>&nbsp;</TD>
  <TD STYLE="text-align: justify; padding-left: 0pt; text-indent: 0pt">&nbsp;</TD></TR>
<TR STYLE="vertical-align: top">
  <TD STYLE="text-align: right; padding-left: 0pt; text-indent: 0pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">2.2. </FONT></TD>
    <TD>&nbsp;</TD>
  <TD STYLE="text-align: justify; padding-left: 0pt; text-indent: 0pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">This Addendum contains the entire agreement between the parties
hereto with respect to the subject matter hereof, supersedes and cancels all prior agreements, arrangements and understandings, written
or oral, relating to the subject matter hereof, if any. In any event of contradiction between the provisions of this Addendum and any
prior agreement, whether written or oral, the provisions of this Addendum shall prevail.</FONT></TD></TR>
<TR STYLE="vertical-align: top">
  <TD STYLE="text-align: right; padding-left: 0pt; text-indent: 0pt">&nbsp;</TD>
    <TD>&nbsp;</TD>
  <TD STYLE="text-align: justify; padding-left: 0pt; text-indent: 0pt">&nbsp;</TD></TR>
<TR STYLE="vertical-align: top">
  <TD STYLE="text-align: right; padding-left: 0pt; text-indent: 0pt">2.3.</TD>
    <TD>&nbsp;</TD>
  <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify; padding-left: 0pt; text-indent: 0pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">This
  Addendum may be amended, modified, superseded, canceled, renewed or extended, and the terms and covenants hereof may be waived, only
  by a written instrument executed by both parties. A waiver of any term or condition of this Addendum may be effected only by a written
  instrument executed by the party waiving compliance. The failure of any party, at any time or times, to require performance of any
  provision of this Addendum shall in no manner affect the right of such party, at a later time, to enforce the same. No waiver by any
  party of the breach of any term or covenant, whether by conduct or otherwise, in any one or more instances, shall be deemed to be,
  or construed as, a further or continuing waiver of any breach, or a waiver of the breach of any other term or covenant.</FONT></TD></TR>
</TABLE>


<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Microbot
Medical LTD. 6 HaYozma St, Yokneam, 2069204. Israel, P.B 242,</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Tel:
972-4-8200710, Fax: 972-4-8200712 <U>www.microbotmedical.com</U></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 3.4in; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>&nbsp;</B></FONT></P>


<!-- Field: Page; Sequence: 1 -->
    <DIV STYLE="margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><IMG SRC="ex10-3_001.jpg" ALT="" STYLE="height: 67px; width: 175px"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" BORDER="0" STYLE="width: 100%; margin-top: 0pt; margin-bottom: 0pt; font: 10pt Times New Roman, Times, Serif">

<TR STYLE="vertical-align: top">
  <TD STYLE="text-align: right; padding-left: 0pt; text-indent: 0pt; width: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">2.4. </FONT></TD>
    <TD STYLE="width: 0.1in">&nbsp;</TD>
  <TD STYLE="text-align: justify; padding-left: 0pt; text-indent: 0pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Except to the extent otherwise specifically modified herein
in this Addendum all of the terms and conditions of the Employment Agreement are hereby ratified, approved and confirmed and all such
terms and conditions shall remain in full force and effect.</FONT></TD></TR>
</TABLE>


<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>IN
WITNESS WHEREOF</B>, the parties execute hereunder:</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="text-align: center; border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; width: 49%"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><I>/s/
    Naama Moav</I></FONT></TD>
    <TD STYLE="text-align: center; padding-bottom: 1.5pt; font: 10pt Times New Roman, Times, Serif; width: 2%"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="text-align: center; border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; width: 49%"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><I>/s/
    Eyal Morag</I></FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="text-align: center; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Microbot
Medical Ltd.</B></FONT></TD>
    <TD STYLE="text-align: center; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="text-align: center; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Eyal Morag</B></FONT></TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1in; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>&nbsp;</B></FONT></P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 3%"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>By:</B>
    </FONT>
</TD>
    <TD STYLE="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; width: 47%"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 50%"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Microbot
Medical LTD. 6 HaYozma St, Yokneam, 2069204. Israel, P.B 242,</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Tel: 972-4-8200710, Fax: 972-4-8200712 <U>www.microbotmedical.com</U></FONT></P>



<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 2.35in; text-align: center; text-indent: -1.9in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>&nbsp;</B></FONT></P>


<!-- Field: Page; Sequence: 2; Options: Last -->
    <DIV STYLE="margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 2.35in; text-align: center; text-indent: -1.9in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

</BODY>
</HTML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-99.1
<SEQUENCE>6
<FILENAME>ex99-1.htm
<TEXT>
<HTML>
<HEAD>
     <TITLE></TITLE>
</HEAD>
<BODY STYLE="font: 10pt Times New Roman, Times, Serif">

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><B STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: right"><B STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Exhibit 99.1</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><B STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><B STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><IMG SRC="ex99-1_001.jpg" ALT="" STYLE="height: 96px; width: 250px"></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><B STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><B STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Microbot Medical Achieved 100% Success Rate for
LIBERTY in Extensive Pre-Clinical Animal Study Performed by Leading European Physicians</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><B STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><I STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">A team of six leading European interventional radiologists
used the LIBERTY<SUP STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&reg;</SUP> Surgical Robotic System and performed a total of 48 catheterizations</I></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><I STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</I></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><B STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">HINGHAM, Mass., May 22, 2023</B> &ndash; Microbot
Medical Inc. (Nasdaq: MBOT), the developer of the LIBERTY<SUP STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&reg;</SUP> Surgical Robotic System, the first single-use endovascular robotic
system, today announced a highly successful extended joint pre-clinical animal study held at a leading European-based research lab.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify">A team of six leading European interventional radiologists
utilized the system and performed a total of 48 catheterizations to pre-determined vascular targets including distal branches of hepatic,
gastric, splenic, mesenteric, renal, and hypogastric arteries, with a 100% success rate of reaching the intended target.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify">Based on real-time user feedback, the interventional
radiologists found the system intuitive, easy to set up and use, and were impressed with the ability to control procedures remotely via
the LIBERTY Robotic System&rsquo;s remote controller.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify">&ldquo;The results of the multi-day study continue
to validate LIBERTY and is further evidence that the on-going adjustments we have made will ensure the safety and efficacy of the system
as we plan to enter the human clinical phase during the second half of the year,&rdquo; commented Dr. Eyal Morag, Chief Medical Officer.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify">&ldquo;We believe this, along with other expected
opportunities for peer-reviewed publications, will lay the foundation of showing the significant benefits LIBERTY is expected to bring
when commercialized and helping to accelerate early adoption.&rdquo; added Dr. Eyal Morag.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify">The Company plans on performing pre-clinical studies
in the U.S. and other target markets, as well as first-in-human case in markets outside the U.S. in preparation for the continued progression
toward commercialization of the LIBERTY Surgical Robotic System.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify">The 48 successful catheterizations are part of the
Company&rsquo;s recent announcement regarding surpassing 100<SUP STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">th</SUP> catheterization during multiple pre-clinical studies, with a
95% success rate of reaching pre-determined vascular targets.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify">&nbsp;</P>


<!-- Field: Page; Sequence: 1 -->
    <DIV STYLE="margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt">&nbsp;</DIV>
    <!-- Field: /Page -->

<P STYLE="text-align: center; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><B STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><B STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><IMG SRC="ex99-1_001.jpg" ALT="" STYLE="height: 96px; width: 250px"></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><B STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><B STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">About Microbot Medical</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify">Microbot Medical Inc. (NASDAQ: MBOT) is a pre-clinical
medical device company that specializes in transformational micro-robotic technologies, with the goals of improving clinical outcomes
for patients and increasing accessibility through the natural and artificial lumens within the human body.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify">The LIBERTY Robotic System aims to improve the way
surgical robotics are being used in endovascular procedures today, by eliminating the need for large, cumbersome, and expensive capital
equipment, while reducing radiation exposure and physician strain. The Company believes the LIBERTY Robotic System&rsquo;s remote operation
has the potential to be the first system to democratize endovascular interventional procedures.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify">Further information about Microbot Medical
is available at <U>http://www.microbotmedical.com</U>.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><B STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><B STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Safe Harbor</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><B STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify">Statements to future financial and/or operating results,
future growth in research, technology, clinical development, and potential opportunities for Microbot Medical Inc. and its subsidiaries,
along with other statements about the future expectations, beliefs, goals, plans, or prospects expressed by management, constitute forward-looking
statements within the meaning of the Private Securities Litigation Reform Act of 1995 and the Federal securities laws. Any statements
that are not historical fact (including, but not limited to statements that contain words such as &ldquo;will,&rdquo; &ldquo;believes,&rdquo;
&ldquo;plans,&rdquo; &ldquo;anticipates,&rdquo; &ldquo;expects&rdquo; and &ldquo;estimates&rdquo;) should also be considered to be forward-looking
statements. Forward-looking statements involve risks and uncertainties, including, without limitation, market conditions, risks inherent
in the development and/or commercialization of LIBERTY, the outcome of its studies to evaluate LIBERTY, whether the Company&rsquo;s core
business focus program and cost reduction plan are sufficient to enable the Company to continue to focus on its LIBERTY technology while
it seeks additional working capital, any failure or inability to recruit physicians and clinicians to serve as primary investigators to
conduct regulatory studies which could adversely affect or delay such studies, uncertainty in the results of pre-clinical and clinical
trials or regulatory pathways and regulatory approvals, uncertainty resulting from the COVID-19 pandemic, need and ability to obtain future
capital, and maintenance of intellectual property rights. Additional information on risks facing Microbot Medical can be found under the
heading &ldquo;Risk Factors&rdquo; in Microbot Medical&rsquo;s periodic reports filed with the Securities and Exchange Commission (SEC),
which are available on the SEC&rsquo;s web site at www.sec.gov. Microbot Medical disclaims any intent or obligation to update these forward-looking
statements, except as required by law.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><B STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Investor Contact:</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><B STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify">Michal Efraty</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify">+972-(0)52-3044404</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify">IR@microbotmedical.com</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify">&nbsp;</P>


<!-- Field: Page; Sequence: 2; Options: Last -->
    <DIV STYLE="margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0">&nbsp;</P>

</BODY>
</HTML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>7
<FILENAME>ex99-1_001.jpg
<TEXT>
begin 644 ex99-1_001.jpg
M_]C_X  02D9)1@ ! 0$ 8 !@  #_VP!#  $! 0$! 0$! 0$! 0$! 0$! 0$!
M 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0'_
MVP!# 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$!
M 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0'_P  1" ![ 4 # 2(  A$! Q$!_\0
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M_@Y1]DLVE@Z.3<48*#]U5L-F.5TL'3KUJ4;.C]8IR2<(J?.W)R^?O@Y^VA\
M_C/'#%X:\86NFZK<1QN=$\126]G>^9(JG:C)+);2KN^59$DC)VL#&HQ7U:DL
M<BI)$Z3(Z%E>)A)N^;.4E3*,!D8+'E1SD\M^2/Q;_P""2?PPU6>[U[X#>+=7
M^#7B1V>XM]-6:>_\*&9FWA&LA(+J"(OM :.1@@ P#TKY>3XA_P#!0?\ 8=O$
MM_'OA34OB3\.+1MHU[1%F\4:4+>,AB\L5MNN]-RK,&$K 0;0&^4 $7B+XE<"
M25/Q3X+HYQDL?<GQMX?TZ^883#QC=*>9<,U)2S3"3G%*4ZV7SQ$(R:4*+;BG
MC+P\\...(.?ACQI7RC.:LG4I\%^(%7#Y?BIN5FZ>7<44X+*\9"FVXPH8Z&'J
M3A%RG67+)G]#$,@"*,NP4#)PH7G.,G/4@'Y5)P2"< @"9R-N[G# 'KC 'S=1
MG!(Z]>E?G'^S]_P4B^ GQDCM--U?6H/ _B>41QW%EJ]Q$FF-<2 C!NI2JVSM
M(-J12_,I(5RK"OT*M=3L]1MX;G3KJWO[6>%9K>[LYX;JVGC958/%- [1ON#!
MEP0",8/-?KW"_&G#'&V7?7^%L[P&;8>-HU/JE>4L1A9)*]+&82K"CCL'5B[P
MJ1Q>%H.-2,H.4I1DW^3<3\'\3\%8S^S^*,ES#*,5)WI/%T5'#XJ#;Y:V"Q=.
MI6P.,HU(VJ4YX3%UE*G.$U",9)+7HJ$2CC*L!DJ#C()'(QZAARN,Y^M!F52H
M(;YLX^[V8KSEO49XR<>_%?5\RNTVDTDW?1)63W?N]=N9OR/G7IOY;)MZZ;)2
M?SM9=6B:BHS* 5X)#$#.1^/'<#N1GGCTRX,#C&>02,^QP1]0>M---73NKVOY
M_<OZ^5S]09PF,YYHWKV.<Y QSG R?T_F*S=9U&TT?2[[5]0E$-CIEK<7MU(5
MW!(+>-I7; 5C\J*3P.N.O2OSZO/^"F'[/UK>36L<FISF*>:WCDACC9',+F*0
MDIE4^9 %!.\H<[5Q5*,I7Y4W;>R_X8&TMS]%@Z$;MPQG&??T^M/KY$_9P_;-
M^"_[4.J^+O#_ ,-=3NIM:\$O$->TO4+8VT\0EV*LL!/$B!FV,<* 1G)!./KE
M&W@D= 2!Z\>OH<YX/-#33::LUNGT =1112 **** "BBB@ HHHH **** "BBB
M@ HHH_S_ (4F[+9OT5P"BD)"C)( XY/N0/\ ]7O41F ( P0<\Y[@C(STR5.0
M/S]Y4KNW)->;22_,":BF*Y;^$@8SD].>GZ<TK-M(_N\EF/\ #@<?G5@.JO*<
M-GKM )Z8!.1@\<<#//'KGBG^:>R$CCZX/\7TZ?K0,2C<.!G'8YXR.>A'/0Y'
M7(Y(J7?2VC]Y7[7B[='U2_7LU))K6/-JM+VZK7Y*[MUVL>'_ !\^%WA[XR_"
M?QM\//%%Q+9:-K^BW$=U?VP!NM.1(F=[RV+9"31JIPPP58?+7X+>'/B'\!?@
M%X3C\+?"OPCI2P6&HZAI,&H3:38Z[XKUZ?3)#:W>NZUJ&HQR7$7G3QM-#!&_
MEQJ^$ !./Z3;FSM[F&XMY LD4T,EM-$5#!XIE9)$8'L0[9'0C (Q7\^'[1W_
M  3#^.FA^/?$7B[]FW5]"\3>#?$^IW&M/X+\33?8[SPWJ-Y,\]['I=TZ.C6<
MLK,ZQH%*J=@48Y_F'Z1G#?B/B\'E7$'AAE&'Q^>TL/6R[.94J.#GF4\%-4YX
M9X-8KXXX>M+$SJ0IOVLX5(Q@TXH_I+Z/'$/ &#Q>;9#XF9MBL!DM2O2S7(Z=
M26*64_VG3<XUX8V6&K4O82Q%'V,*56MST8.G*ZBY.3?\!/\ @H'XA^'GQ3\+
M>'/$ECIMY\+/B'X@MO#L\MKI-II.K:!K=ZWEV5Q)'8PQPW-O)G$AD!DP.6VY
MK^A*WN8YHXI8SNCEBCDC?H61U#)P0"<JP/MN]Z_GY_9?_P""6WQBU'XI>#_B
M;^U'KFA6'AGX?:E'X@\,_#/PQ(;N+4M?0J;>^UR[4QKY=L?F$#B3!5< 9-?T
M%+;QHBQH%5%"JBJH 557:%7T &  ,#CIR<^O]&_*?%/*N#,12\4ZV(GF%7-J
M^(RG#8UT5C<!EE2FO]DJPH2E&G2C7O+#49/FI4W*+2NCR_I$9EX89GQMAJOA
M?2P\,MH972PV:U\%2JTL%C<PIU+PQ5*56I4]M5EAY2AB:\'&-2I"$DGNYZ*;
MD(/F;\2?0?X G\Z:')4$#=\V&"\XZ\_RS]:_H=7O*_=6]+?U<_ B2BHTDW''
M /7&><>OTY ^N:DI]7OI:VBMJNCW?GZV JR(#(Q.2-JAASR"<'IU^7Z?C52:
MUBGAFM[B&&:VE22*>WGCCDMY$<$-')#(K1NC E65E._=@@@FM(I\Q;/4$$8[
M8.,>XX_7UJ,H"2&())&.AR2-QRI'8?,![>P%1RI1LE)QEK./+3?-)VYN95%*
M-_=6RM>STL3*-W%VC*4?AE-S3COHN247;7O=)NSNS\]/V@?^"<7[//QP>?5M
M/T5OAGXY<-):^*/!@73XVN(B94%YI<>VQG4R8E9EB20*&())P?@"Z\#_ +?_
M .PK)=ZGX9NKGXS_  JL6$L[Z6TFH36FFKE&.H:5-FZ@E0>7SI\;988C8J17
M] @148\<'E@#C=@]< X)R,DD<C(/0"E6VQSO)5QED;Y@3G()#%AQP,#C(R .
MM?DO$W@SPEQ#C?[=R]9AP9Q7&_LN)>#<3/(\P;UE'Z_1P\J>7YK'GLYPQV J
MJ=ZL5-<_,?J_#/C#Q=D.!_L',G@.,.$VE[3AKC'#+/, ER\K_L^M74\QRF2C
MS*G4P6/I.+]DU"T%!_F-^SY_P4U^"WQ=:QT/QE<2?#[Q9,XMY+75$FM;26[9
M\",13H+FW&'7)F501EBV.:_22QO;'5+2VU'3[VUU&SE*2P7=I+'<0/"X5D:)
MXF= ,')R<^H!.*^+_P!H+]@']GG]H'[7K.H>&HO _CJ5#/#XX\%Q)HFJ2793
M<D^I1V8ABU(!MIG25$9T#1L[97'YN:AX&_;Q_8)OY-1\(:CJ/QL^#]O(S,-/
M-Q?3V]C$^_&HZ)(TSV31Q#'VF%G88. .M?+?ZS>*_AO&-+CG)H>(_"N&<84>
M,>#\%4CQ%A$Y17M,ZX2@_98E48WG/$Y3B9R483<:<JCA%_0_ZK^%7B+=\#9M
M5\.>*\2I5:O"7&&/I/(,<X1;C2R;BN;]MA75E:E3P^;4(0O4BIU84^>4?Z#5
MQA=VWKCD]CD@@]<Y4 ],]?8RKC&./E].@XSD>V"/UK\T/V=O^"E'P=^+QM=!
M\4SQ^ ?&2E8KFRU>1H+-KLJ8C$IN5CECD>;=&Z% JNR$DX-?HU;:C%>PV]U:
MRP7-M,H:.>WD2:*4,,AD>,NF,#*Y.2!^?ZSPMQMPSQME_P!?X9SG YE&E/DQ
M="G6C1QF KQ5YX7,,!6E#&8/%0^&="O13C*+C[25C\NXGX-XFX+QRRWB3)\?
MEM::]IA:M:A.>"QU!_#B<OQ]*,\#CL+.W-"OA<34C.+4E YKXH'_ (MSXX88
M('A;6S@Y()%A/C(&,KZX.>F#7\,/B S+KNK*MW>(HUO62J)=3!48ZDX.P!P4
M52!L48P,CH>?[EOB7,S_  [\; C*MX5UMN ?N_8)OF! QC.1UXXR?3^&G7]S
M:[JS<8&NZRO.1C.IRD8R.>G)X R.U?;X2SA-2E'VM_A3]Y+HW'6RZ7O+71M;
MGR\VDFGI=^[=Z3:U:B];M+5KW6EKKL?JE_P0U#/\>_CH&=W/]C6KEW=V?<DL
M0))S\Y);DMU&>!7]0RKM4#.3SDGJ23DDU_+S_P $-25^/OQT!4_\@.#/T::(
MCIG'0=?7'7-?U!,[$D(02#@KC)XZGZ=!6%5\LY7UN[Z:_EM\^HX_"O0FHJ,R
MJ K'H?TX[_R_/TIX.0#Z@'CI6:E?[,EZJR_,H6BBFLVU2V"<=AU//:J =14)
MF&..O((/!5L C.>W/.?:A6=F']WG)P#TQU(..3D>O'3TERMI:3TOHFU]_<":
MF.Q7 4;F) QV&>Y]!U_(^AI]0.073&06* \G& S/C&<9RF"?0FDIIM*S3=[)
MK71V?W7_ % <9""<+N'&T@@9XSW_ ,X!- D(!WJPQD\ D!0,Y8C(4]3@GICU
MK^;#]M_]M?XU_#C]HSQ_X+T#Q/K5CHNAZA9P:5;Z;J<]C%&EQ;F<QM#&P4LK
M,1YGWG!"\8P/)?V6OV]?VB/$W[8/P;\(:AXSUN]\%^+;>^L=>\.ZG?37\=],
MKQF.ZCDN/,VM&)2N.-H10IP,#=4JC7,HZ;WNNJOW[$N23L_R/ZK5;<H;!&1G
M!QD>W&1^5+3,[8]V!\J%L 8' R !V Z4X'(!/< UF4+7Y)?%_P#X*D>'?AG\
M0O%?@:'PK:W3^%=7?1KN:\U$P2O.B!C(J# "L<[5],#.>3^MB]!]!_*OXJ/V
MU8XW_:E^.9>.-\>-@?G4$<QID\]."W/;)]36F&BIKWE=N,+:NUVE?3OJMWJ3
M*26_6]C]U_A3_P %6_#_ ,0OB%?^"+WX?306-EX;N]>;Q+8:G%)IB2VJK*;"
MYDFRD;8!1GR"-X(4D!6\7^+'_!7.YT+5[JQ\&1^' D$TT2Q-87.JK&89-@22
M\BF6*9FP#E40#D@@$8_GITS3?B'XN\6^$O@[\)+BXLO&OQ-O5TQ9K*1X4M='
M>0F\N[@Q'+,Z(@9#\HQ@C ;/ZG^.O^"*WQ5^$WPEU/XAZ+\6U\3^*_#>DS:Y
MK_AF>-A;W<5M +J^A@EV[6E14?80P8[B2< XWE"DFH;.6B:UW]?N_I7E.5E)
MO3=]]/D?7/PZ_P""S]O!JUO9_%SP1:_\(]-<10S>)/##SQ3V D<*MU=:?(\H
MD@C7)D52I('7CG]%?B-^W)\(_"/@W3?&'A[4[?Q+I^MZ<-2T^]>Y2RTR*WEB
M22(S33L7FGRQ4P)@AE(R.*_CF1TN84G\I8/. WV\RD.)L[)(YEZE5<.-G1@O
M!.,UZC\,OAQ\<?VT/BIX=_9P\#^)9],\,>&K&*]UB_*M%INCV,S+A$B4%)77
M$FT,#@@@'+ &94:<4Y.4[+>RC<I23=M3]D?%G_!8?Q%:ZC<Q^&K;PW+;PL-J
M2:3J$R$X)V-,)@IW$@[U;80R\C!8^Q? ?_@L1X-\3^*=(\&_&;P[;^"QKMU'
M8Z;XRTZ5SH:WEPRQV\-];3EWM]SGF0RJH'\+5^8O[4/_  2\^('[('P_M_B7
MIOQ!?XA^%HKNTL/$]G<QE+C3WG!BCNH%* M 9EP54_*I(.T8Q^=.LV,=_I&H
MVQSMEMFDADZ>1<1;9DFBVD,CKM4+*IR#SE1@%*G3FFX<[L[>]9*W6SC?5#;2
M5V?WYV=W;7]M'=6-S%=6U]%'<VUY;,KP7$4J*5DBE1B&5BP92#S]W& 37Y>?
M'?\ X*4^'?@S\3/%/PX3PQ!>W'A6[AL[V>\OQ;-/+<1B7?&H;<456QGDGN<]
M.E_X)2?%_5OBW^R+X'N/$-U)>ZIX9'_"/2W,LC232QVH*0&1R!OQ'U;+$]2>
M./P;_P""C,<1_:V^++&./=_:-BXRH/W[.)"6P/F.W;U!P>E9PIIS<9-:)K2,
M92NWJXRFG[-I:<R3>MK6)E+1-.2;6EFN7_M^#C)3797BT];ZV/V5^#'_  54
M\)_%+X[^#_@A>^#_ .SY?&%K<W5AX@M-02YM8)K<JRVTL8W!C(<*&&""<YX&
M?UW:X*Y)V! ,EB?E1<;@TCEE"#;UX.WECQ@'^)7]BF&(?MQ_ A8(U3$UX!QE
M0&$3$D G@\[L'D 8R37]*W[?7[4<'P/\)0>&M-O#:ZOK=E+>ZC-$62[ATJ/Y
M(;>(J2ZR:A-^[<\%(SD$;N5[%QJ.*DFI:J\81:LM>:<(QYV]-7%6V2U'&7,O
MM76[<DXMOK&,8Q4/-:W>MSUCXS_ME_#+X3I=0/>V>L7UJ)1<,+V*TL+::(,!
M";J4[+A@P8;8CR>#@\5^8?C3_@L!J5M=S)X8MO#KPJ[B,#3+ZX8X)4#[0LQA
M=<<EE"EB#C (Q^%7Q8^+>L^,);_QIXXU.X.D0-/)::#'+(;:WB>8FVMTA!_>
MW4V1AF#2,S@;B>!]%?LN_P#!-W]JG]K?0+?Q\=0M/A!\.KX;=!AO+=H]7U"S
M7#K>-&Z\&=6!!!X('')VZQITUI5DU*_V7I;INM]QIIJZ/TMT/_@M3K&@^;J?
MCOP)I&N>'+-T74IM!-SIFJV\4K>6LZQ3M,D@3=N.U2WR')7(:OV8M?V@?"6K
M?L_/^T+HJ7%YX8_X1$^+$LV<I<K;^5&XMY&&,/&S;9&P-W).WJO\U7QG_P""
M+O[47@OPAJ=W\/O'.D?$DO;*KZ->HL%Y*-\9=H& ^9PN=V3@%0,9QG]E?#W@
M3Q%\,_\ @F?X@\%^*[1]/U_1/A/?6NJ6DN"UO<+$@EB+<<*RG' P #]<ZD(.
M4%2=U?5M_%J]-+/39>H[Z-]CQ)O^"OWA_P QU7P=I?EXDEB=M8VNT2Y\M)5W
M8CD?!'?YN O!SZ7\/_\ @J-X3\<_!_5?B5>>";CPG<Z;KEYH176+]4TZ9K<&
M-+ZTE.'N_-P9$MD.=K("^<Y_EPFMX3,Z_9X?]82C%0<MO08?@_*,DC/\1X&<
M5N>!_"'QO_:+\>6'[/?P1L[G6;BU0W^K7%U++_PC7AB"78_VJ6-/W7VWR6C;
MY]SC&,$G)WG0I03DW.SM*RMI?=*_^9*FFU:^I^T_C_\ X+.>,/#EOK.M>&]%
M\,:]8Z+%-<#37TV^MUU*-9%79%="8A=J.2S[TWEE'IG]I?V:OC[;?'KX#>"O
MC1=Z?#X5@\2:*FJZC8SRG[+I84$RHMQ*3N0\;-S%@HZ<BOYNM5_X(?\ [6UU
MX:\AOBSX6NI]06W35=)5?(B%J)K9YC;OLV[EA+HP)W')RK$ #["_:C^-R?LH
M_!CP-^S'X;F%Q>_#SPG8VGB%+"8P_P!L^)+B!($L24('V:V:1;L\@%64OD
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M7X>1Z>OBWQQ<7 M;C43BVB"$X9@.02P,AS]XL.0#QTN2]G*U[6T]$K6W]/\
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M!7ZS?\$,B#\9/V@R/[EEU'L >H_7'7D5O6O&FW;1I?C;_@HE1Y9+6^Y^N_\
MP4M16_8[^)V\*V&TPC(! /VU ,9SS\Q'J"2*_D*N<"*YP ,6L@ P. ?-! QP
M,C@XZU_7U_P4LY_8Z^*&.>=(''K]NAXK^0B^&([W((S92 <$?,(7R.GW@<''
M4=:SPTKP?1-I^G3_ ()4_A^:_4_I,_X(<X_X90NL\X\4W0YYP%$N![  # ]
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M0&9B!CGGO7\&UO/8:Y81SV,LK*LL<\3K\MYI]PC>8$:/Y6@GMKA!\C8(QM;
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M^J>*_P!EWQI<>#$OGGNY?!.K.UYHZW#$ 069N3)Y%OA?E53SU."17YR^)?\
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M\ML881[BJ $J<$_N'965K8VUO965M%;VUI$D<-M'&L*1QPH4C1$4;%53M"A
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M/1/!WBC4_#>J> OB-X0LI])\2> M8L9[&\@M'N&DCU9!=L&$<C-@*BE3RH)
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*WNM2?Y%%%(#_V0$!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>8
<FILENAME>ex10-3_001.jpg
<TEXT>
begin 644 ex10-3_001.jpg
M_]C_X  02D9)1@ ! 0$ 8 !@  #_VP!#  $! 0$! 0$! 0$! 0$! 0$! 0$!
M 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0'_
MVP!# 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$!
M 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0'_P  1" !S 2P# 2(  A$! Q$!_\0
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M^RZ' =-5-E5I#@C*A/FX&,%B?P'<]^_>I3<("05<8Z_*<C.,9';KS_=XSUJ
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M2PBK2G!?L\KY QC'0GZ'' ZG'Z'M7\T__!9\?\7J\ C 8#P;<$;OFZ2<D$Y
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M^<A5<A7\P[00WS$D#^9O_@H)^R!H?[(_QH@L/A^9Q\+?B!83:_X>T>YD>?\
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MX>^+NIZ)K&FVWP(^*2W6I61MX8WT:;:MU(D:E"_E_+''P&Q\I&<$<D_V8_\
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MSZ5_*3K_ (2^+VNZ1/HMC\"?B:+S5KJTMH&ET>=421[E&?SV5/W<<3[MVT]
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M3]F[_@HI^SC^TUX@;P5X2UZ?0?&[)NM/"OB>!M,O+T1;B\-I'<+$3=*,L+7
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M$RG1=)UZ]T_5]/UMS'I#^+[4J=*BU82NFS3+V10ZW$O[F2-USD$D?MW\!_\
M@DS\#_A7\1]/^+OQ!\4^-OCQ\1=#EAF\/:U\2-0^W6NARP+MM;FRTY ML+NV
M92T,^W<C$=N*[']K/_@F9\ OVJO$J^/M2N-<^'GQ+%O#;7?B[P=,+-M:BMMK
M6IUBR*_9[R:  >7<@+*0N"2,TO:1]Y*_O0DKVZW5NNFSOJ]6]+;!^9O_  5U
M^#W[-'A?PAX.\6_"/2?!7ASQR@N+&^MO!,EE%!J_A^2$*AN;:QD:WG,(4;9B
MJNJ[26/)KSK]KF-Y?^":O[("?9S(J:7JA\L;&QBUF 7.[+=0I0@*> "S 5]Q
M+_P0Z^ =_P"&VL/%OQ8^,7B7Q!-* _B>YUTB5;(\"QBT]M]I#"5.W<JK@=N!
MCZ?^+/\ P3;^#?Q<_9]^&O[/&M>*_&>F^&OA4OE:%K.E:A'#K4T+_NIDOY64
MI,9%8@,%&&"ELCBB$XITKNW*ZG-H]&]GIU\TO+3J=OZ_S_+Y'X0?M1>)/'>D
M_L(?L4:'I$]Y9> _$_@6:&YNK)VAL)M;BG*W%H\R81)S#DQ))M60KA0<9K]A
MOV0/@S^P./V2_ LLFB?"?7-(FT+3+[QKK'BH:2^MP^)9'A:^&I7%SMOK5X-2
M"B+$BH2 ZL23CZPTS]BOX&#]FGP]^RQXKTB3QS\-_#.EIIFE2Z\^_6K5X69H
M=2MK^!4EM=0@:0N9X&4-D;U*Y!_/.7_@AW\(5U![6P^/'Q?L/ 5QJ5IJ%WX,
M@U2&*SO8[2XBN8]/NKB(+)-:,\2*02&"*>=SM0YQ<9+F:;JN5TGJK))IO75J
M[^'YV"W]?U^I^:7[9@LO$?[>^F> /C5=WEE\']$\5>'8X;(2.UD?AO=10G3;
MG3$.U)=+=$5))H"T<<;,YQG-?HY_P42^!7[&=G^RA!XB^&VB_#OP_P")] FT
MB?X?:]X2?3UU.YB8PQWUI<"VF5]2%[9MMFBN%8I+B1R!&\;?=G[3/_!/CX!_
MM3>&O"&C^-;35M&\5> ]#M_#WA7X@>'+@V?B6UTFWM(K5;.[N /+U&UD2$'R
MKL.4<R%"-W/QQH?_  0\^"(TG4--\:_&#XO^+IW0Q^'[B?73:0^'%R-QL-/0
MFSE9HU".TL;,49OF7)S*FN:EO[JLWKTDW^M_.UF!^?GAD/)_P2 /[K8Q^.%V
MSPJT>"S*V8P5; +8)R <;@0"#FOU _X(L;H_V-B"ACS\2/%Z8RK@YN(@0I4[
M5&[(/]WH1G%>L6W_  3)^#%G^RK+^R>?%/C@^#)/%$GBV+7QJ$2>)8]8D)(<
M3A#$80QSY.W;@  =<_0_[)_[*W@O]D3X4I\)/ .K:UK&A1ZYJ.NB^\03K/J,
MEWJ+QO/YLD05&&Y&. !\Q!ZYQ,Y1;]WK.36G1W[V:VOL!]0J00"#D'D'U!Y'
MX<\>U+34&U57^ZJC],=>_0TZI **** "BBB@ HHHH **** "BBB@ HHHH **
M** "BBB@ HHHH **** "BBB@ HHHH *BFR(W8$@JI92"1R!QG! (]FR#W%%%
M);?-_FP$B)95))RT<3'G W'<Q.!@#)ZX ST/  ILBAF.<\1%AAF7# \'Y2.1
MC@]0,@<$T44P(V8J^0>L&\]QO"MA@#D \<XQGOFGH<K;Y _>??\ E4;L1LPX
M P/F /&.F.G%%%);+^NX$KHI XQ\R_=)4\L >5(/(.#Z_@*HPR.UP8F(*+N
M!520 7P-V-W&!U-%%,"TL:R%]V[Y9"JA7=   ",!&4 Y)YQD]STILJ*$$G.]
M' 5BS$@><%P<D[N#@[L\<444 );,9D8R8<AP 2!Q@ CH!W_PZ5;HHH ****
#/__9

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.SCH
<SEQUENCE>9
<FILENAME>mbot-20230518.xsd
<DESCRIPTION>XBRL SCHEMA FILE
<TEXT>
<XBRL>
<?xml version="1.0" encoding="US-ASCII" ?>
    <!-- Field: Doc-Info; Name: Generator; Value: GoFiler Complete; Version: 5.18b -->
    <!-- Field: Doc-Info; Name: VendorURI; Value: https://www.novaworks.com -->
    <!-- Field: Doc-Info; Name: Status; Value: 0x00000000 -->
    <!-- Field: Doc-Info; Name: Misc; Value: 96Mps7xRiXgen8uDanwsWaSBKbP9z5Z8mekhvWB5bRnajygrkGkVqSGbP9rWAXAD -->
<schema xmlns="http://www.w3.org/2001/XMLSchema" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:xbrli="http://www.xbrl.org/2003/instance" xmlns:xbrldt="http://xbrl.org/2005/xbrldt" xmlns:xbrldi="http://xbrl.org/2006/xbrldi" xmlns:dei="http://xbrl.sec.gov/dei/2022" xmlns:us-gaap="http://fasb.org/srt-sup/2022q3" xmlns:srt="http://fasb.org/srt/2022" xmlns:srt-types="http://fasb.org/srt-types/2022" xmlns:MBOT="http://microbotmedical.com/20230518" elementFormDefault="qualified" targetNamespace="http://microbotmedical.com/20230518">
    <annotation>
      <appinfo>
	<link:roleType roleURI="http://microbotmedical.com/role/Cover" id="Cover">
	  <link:definition>00000001 - Document - Cover</link:definition>
	  <link:usedOn>link:presentationLink</link:usedOn>
	  <link:usedOn>link:calculationLink</link:usedOn>
	  <link:usedOn>link:definitionLink</link:usedOn>
	</link:roleType>
	<link:linkbaseRef xlink:type="simple" xlink:href="mbot-20230518_pre.xml" xlink:role="http://www.xbrl.org/2003/role/presentationLinkbaseRef" xlink:arcrole="http://www.w3.org/1999/xlink/properties/linkbase" xlink:title="Presentation Links" />
	<link:linkbaseRef xlink:type="simple" xlink:href="mbot-20230518_lab.xml" xlink:role="http://www.xbrl.org/2003/role/labelLinkbaseRef" xlink:arcrole="http://www.w3.org/1999/xlink/properties/linkbase" xlink:title="Label Links" />
      </appinfo>
    </annotation>
    <import namespace="http://www.xbrl.org/2003/instance" schemaLocation="http://www.xbrl.org/2003/xbrl-instance-2003-12-31.xsd" />
    <import namespace="http://www.xbrl.org/2003/linkbase" schemaLocation="http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd" />
    <import namespace="http://xbrl.sec.gov/dei/2022" schemaLocation="https://xbrl.sec.gov/dei/2022/dei-2022.xsd" />
    <import namespace="http://fasb.org/us-gaap/2022" schemaLocation="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd" />
    <import namespace="http://fasb.org/us-gaap-sup/2022q3" schemaLocation="https://xbrl.fasb.org/us-gaap/2022q3/us-gaap-sup-2022q3.xsd" />
    <import namespace="http://fasb.org/srt-sup/2022q3" schemaLocation="https://xbrl.fasb.org/srt/2022q3/srt-sup-2022q3.xsd" />
    <import namespace="http://fasb.org/us-types/2022" schemaLocation="https://xbrl.fasb.org/us-gaap/2022/elts/us-types-2022.xsd" />
    <import namespace="http://www.xbrl.org/dtr/type/2020-01-21" schemaLocation="https://www.xbrl.org/dtr/type/2020-01-21/types.xsd" />
    <import namespace="http://xbrl.sec.gov/country/2022" schemaLocation="https://xbrl.sec.gov/country/2022/country-2022.xsd" />
    <import namespace="http://fasb.org/srt/2022" schemaLocation="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd" />
    <import namespace="http://fasb.org/srt-types/2022" schemaLocation="https://xbrl.fasb.org/srt/2022/elts/srt-types-2022.xsd" />
</schema>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.LAB
<SEQUENCE>10
<FILENAME>mbot-20230518_lab.xml
<DESCRIPTION>XBRL LABEL FILE
<TEXT>
<XBRL>
<?xml version="1.0" encoding="US-ASCII" standalone="no"?>
    <!-- Field: Doc-Info; Name: Generator; Value: GoFiler Complete; Version: 5.18b -->
    <!-- Field: Doc-Info; Name: VendorURI; Value: https://www.novaworks.com -->
    <!-- Field: Doc-Info; Name: Status; Value: 0x00000000 -->
<link:linkbase xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:xbrli="http://www.xbrl.org/2003/instance" xsi:schemaLocation="http://www.xbrl.org/2003/linkbase http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd">
    <link:roleRef xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedLabel" roleURI="http://www.xbrl.org/2009/role/negatedLabel" />
    <link:roleRef xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedPeriodEndLabel" roleURI="http://www.xbrl.org/2009/role/negatedPeriodEndLabel" />
    <link:roleRef xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedPeriodStartLabel" roleURI="http://www.xbrl.org/2009/role/negatedPeriodStartLabel" />
    <link:roleRef xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedTotalLabel" roleURI="http://www.xbrl.org/2009/role/negatedTotalLabel" />
    <link:roleRef xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedNetLabel" roleURI="http://www.xbrl.org/2009/role/negatedNetLabel" />
    <link:roleRef xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedTerseLabel" roleURI="http://www.xbrl.org/2009/role/negatedTerseLabel" />
    <link:roleRef xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/net-2009-12-16.xsd#netLabel" roleURI="http://www.xbrl.org/2009/role/netLabel" />
    <link:labelLink xlink:type="extended" xlink:role="http://www.xbrl.org/2003/role/link">
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_CoverAbstract" xlink:label="dei_CoverAbstract" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_CoverAbstract" xlink:to="dei_CoverAbstract_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_CoverAbstract_lbl" xml:lang="en-US">Cover [Abstract]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_DocumentType" xlink:label="dei_DocumentType" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_DocumentType" xlink:to="dei_DocumentType_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_DocumentType_lbl" xml:lang="en-US">Document Type</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_AmendmentFlag" xlink:label="dei_AmendmentFlag" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_AmendmentFlag" xlink:to="dei_AmendmentFlag_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_AmendmentFlag_lbl" xml:lang="en-US">Amendment Flag</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_AmendmentDescription" xlink:label="dei_AmendmentDescription" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_AmendmentDescription" xlink:to="dei_AmendmentDescription_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_AmendmentDescription_lbl" xml:lang="en-US">Amendment Description</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_DocumentRegistrationStatement" xlink:label="dei_DocumentRegistrationStatement" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_DocumentRegistrationStatement" xlink:to="dei_DocumentRegistrationStatement_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_DocumentRegistrationStatement_lbl" xml:lang="en-US">Document Registration Statement</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_DocumentAnnualReport" xlink:label="dei_DocumentAnnualReport" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_DocumentAnnualReport" xlink:to="dei_DocumentAnnualReport_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_DocumentAnnualReport_lbl" xml:lang="en-US">Document Annual Report</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_DocumentQuarterlyReport" xlink:label="dei_DocumentQuarterlyReport" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_DocumentQuarterlyReport" xlink:to="dei_DocumentQuarterlyReport_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_DocumentQuarterlyReport_lbl" xml:lang="en-US">Document Quarterly Report</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_DocumentTransitionReport" xlink:label="dei_DocumentTransitionReport" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_DocumentTransitionReport" xlink:to="dei_DocumentTransitionReport_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_DocumentTransitionReport_lbl" xml:lang="en-US">Document Transition Report</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_DocumentShellCompanyReport" xlink:label="dei_DocumentShellCompanyReport" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_DocumentShellCompanyReport" xlink:to="dei_DocumentShellCompanyReport_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_DocumentShellCompanyReport_lbl" xml:lang="en-US">Document Shell Company Report</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_DocumentShellCompanyEventDate" xlink:label="dei_DocumentShellCompanyEventDate" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_DocumentShellCompanyEventDate" xlink:to="dei_DocumentShellCompanyEventDate_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_DocumentShellCompanyEventDate_lbl" xml:lang="en-US">Document Shell Company Event Date</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_DocumentPeriodStartDate" xlink:label="dei_DocumentPeriodStartDate" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_DocumentPeriodStartDate" xlink:to="dei_DocumentPeriodStartDate_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_DocumentPeriodStartDate_lbl" xml:lang="en-US">Document Period Start Date</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_DocumentPeriodEndDate" xlink:label="dei_DocumentPeriodEndDate" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_DocumentPeriodEndDate" xlink:to="dei_DocumentPeriodEndDate_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_DocumentPeriodEndDate_lbl" xml:lang="en-US">Document Period End Date</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_DocumentFiscalPeriodFocus" xlink:label="dei_DocumentFiscalPeriodFocus" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_DocumentFiscalPeriodFocus" xlink:to="dei_DocumentFiscalPeriodFocus_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_DocumentFiscalPeriodFocus_lbl" xml:lang="en-US">Document Fiscal Period Focus</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_DocumentFiscalYearFocus" xlink:label="dei_DocumentFiscalYearFocus" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_DocumentFiscalYearFocus" xlink:to="dei_DocumentFiscalYearFocus_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_DocumentFiscalYearFocus_lbl" xml:lang="en-US">Document Fiscal Year Focus</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_CurrentFiscalYearEndDate" xlink:label="dei_CurrentFiscalYearEndDate" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_CurrentFiscalYearEndDate" xlink:to="dei_CurrentFiscalYearEndDate_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_CurrentFiscalYearEndDate_lbl" xml:lang="en-US">Current Fiscal Year End Date</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityFileNumber" xlink:label="dei_EntityFileNumber" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityFileNumber" xlink:to="dei_EntityFileNumber_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityFileNumber_lbl" xml:lang="en-US">Entity File Number</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityRegistrantName" xlink:label="dei_EntityRegistrantName" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityRegistrantName" xlink:to="dei_EntityRegistrantName_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityRegistrantName_lbl" xml:lang="en-US">Entity Registrant Name</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityCentralIndexKey" xlink:label="dei_EntityCentralIndexKey" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityCentralIndexKey" xlink:to="dei_EntityCentralIndexKey_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityCentralIndexKey_lbl" xml:lang="en-US">Entity Central Index Key</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityPrimarySicNumber" xlink:label="dei_EntityPrimarySicNumber" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityPrimarySicNumber" xlink:to="dei_EntityPrimarySicNumber_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityPrimarySicNumber_lbl" xml:lang="en-US">Entity Primary SIC Number</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityTaxIdentificationNumber" xlink:label="dei_EntityTaxIdentificationNumber" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityTaxIdentificationNumber" xlink:to="dei_EntityTaxIdentificationNumber_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityTaxIdentificationNumber_lbl" xml:lang="en-US">Entity Tax Identification Number</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityIncorporationStateCountryCode" xlink:label="dei_EntityIncorporationStateCountryCode" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityIncorporationStateCountryCode" xlink:to="dei_EntityIncorporationStateCountryCode_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityIncorporationStateCountryCode_lbl" xml:lang="en-US">Entity Incorporation, State or Country Code</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityAddressAddressLine1" xlink:label="dei_EntityAddressAddressLine1" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityAddressAddressLine1" xlink:to="dei_EntityAddressAddressLine1_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityAddressAddressLine1_lbl" xml:lang="en-US">Entity Address, Address Line One</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityAddressAddressLine2" xlink:label="dei_EntityAddressAddressLine2" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityAddressAddressLine2" xlink:to="dei_EntityAddressAddressLine2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityAddressAddressLine2_lbl" xml:lang="en-US">Entity Address, Address Line Two</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityAddressAddressLine3" xlink:label="dei_EntityAddressAddressLine3" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityAddressAddressLine3" xlink:to="dei_EntityAddressAddressLine3_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityAddressAddressLine3_lbl" xml:lang="en-US">Entity Address, Address Line Three</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityAddressCityOrTown" xlink:label="dei_EntityAddressCityOrTown" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityAddressCityOrTown" xlink:to="dei_EntityAddressCityOrTown_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityAddressCityOrTown_lbl" xml:lang="en-US">Entity Address, City or Town</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityAddressStateOrProvince" xlink:label="dei_EntityAddressStateOrProvince" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityAddressStateOrProvince" xlink:to="dei_EntityAddressStateOrProvince_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityAddressStateOrProvince_lbl" xml:lang="en-US">Entity Address, State or Province</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityAddressCountry" xlink:label="dei_EntityAddressCountry" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityAddressCountry" xlink:to="dei_EntityAddressCountry_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityAddressCountry_lbl" xml:lang="en-US">Entity Address, Country</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityAddressPostalZipCode" xlink:label="dei_EntityAddressPostalZipCode" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityAddressPostalZipCode" xlink:to="dei_EntityAddressPostalZipCode_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityAddressPostalZipCode_lbl" xml:lang="en-US">Entity Address, Postal Zip Code</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_CountryRegion" xlink:label="dei_CountryRegion" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_CountryRegion" xlink:to="dei_CountryRegion_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_CountryRegion_lbl" xml:lang="en-US">Country Region</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_CityAreaCode" xlink:label="dei_CityAreaCode" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_CityAreaCode" xlink:to="dei_CityAreaCode_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_CityAreaCode_lbl" xml:lang="en-US">City Area Code</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_LocalPhoneNumber" xlink:label="dei_LocalPhoneNumber" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_LocalPhoneNumber" xlink:to="dei_LocalPhoneNumber_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_LocalPhoneNumber_lbl" xml:lang="en-US">Local Phone Number</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_Extension" xlink:label="dei_Extension" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_Extension" xlink:to="dei_Extension_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_Extension_lbl" xml:lang="en-US">Extension</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_WrittenCommunications" xlink:label="dei_WrittenCommunications" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_WrittenCommunications" xlink:to="dei_WrittenCommunications_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_WrittenCommunications_lbl" xml:lang="en-US">Written Communications</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_SolicitingMaterial" xlink:label="dei_SolicitingMaterial" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_SolicitingMaterial" xlink:to="dei_SolicitingMaterial_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_SolicitingMaterial_lbl" xml:lang="en-US">Soliciting Material</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_PreCommencementTenderOffer" xlink:label="dei_PreCommencementTenderOffer" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_PreCommencementTenderOffer" xlink:to="dei_PreCommencementTenderOffer_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_PreCommencementTenderOffer_lbl" xml:lang="en-US">Pre-commencement Tender Offer</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_PreCommencementIssuerTenderOffer" xlink:label="dei_PreCommencementIssuerTenderOffer" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_PreCommencementIssuerTenderOffer" xlink:to="dei_PreCommencementIssuerTenderOffer_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_PreCommencementIssuerTenderOffer_lbl" xml:lang="en-US">Pre-commencement Issuer Tender Offer</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_Security12bTitle" xlink:label="dei_Security12bTitle" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_Security12bTitle" xlink:to="dei_Security12bTitle_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_Security12bTitle_lbl" xml:lang="en-US">Title of 12(b) Security</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_NoTradingSymbolFlag" xlink:label="dei_NoTradingSymbolFlag" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_NoTradingSymbolFlag" xlink:to="dei_NoTradingSymbolFlag_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_NoTradingSymbolFlag_lbl" xml:lang="en-US">No Trading Symbol Flag</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_TradingSymbol" xlink:label="dei_TradingSymbol" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_TradingSymbol" xlink:to="dei_TradingSymbol_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_TradingSymbol_lbl" xml:lang="en-US">Trading Symbol</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_SecurityExchangeName" xlink:label="dei_SecurityExchangeName" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_SecurityExchangeName" xlink:to="dei_SecurityExchangeName_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_SecurityExchangeName_lbl" xml:lang="en-US">Security Exchange Name</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_Security12gTitle" xlink:label="dei_Security12gTitle" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_Security12gTitle" xlink:to="dei_Security12gTitle_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_Security12gTitle_lbl" xml:lang="en-US">Title of 12(g) Security</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_SecurityReportingObligation" xlink:label="dei_SecurityReportingObligation" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_SecurityReportingObligation" xlink:to="dei_SecurityReportingObligation_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_SecurityReportingObligation_lbl" xml:lang="en-US">Security Reporting Obligation</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_AnnualInformationForm" xlink:label="dei_AnnualInformationForm" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_AnnualInformationForm" xlink:to="dei_AnnualInformationForm_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_AnnualInformationForm_lbl" xml:lang="en-US">Annual Information Form</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_AuditedAnnualFinancialStatements" xlink:label="dei_AuditedAnnualFinancialStatements" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_AuditedAnnualFinancialStatements" xlink:to="dei_AuditedAnnualFinancialStatements_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_AuditedAnnualFinancialStatements_lbl" xml:lang="en-US">Audited Annual Financial Statements</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityWellKnownSeasonedIssuer" xlink:label="dei_EntityWellKnownSeasonedIssuer" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityWellKnownSeasonedIssuer" xlink:to="dei_EntityWellKnownSeasonedIssuer_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityWellKnownSeasonedIssuer_lbl" xml:lang="en-US">Entity Well-known Seasoned Issuer</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityVoluntaryFilers" xlink:label="dei_EntityVoluntaryFilers" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityVoluntaryFilers" xlink:to="dei_EntityVoluntaryFilers_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityVoluntaryFilers_lbl" xml:lang="en-US">Entity Voluntary Filers</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityCurrentReportingStatus" xlink:label="dei_EntityCurrentReportingStatus" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityCurrentReportingStatus" xlink:to="dei_EntityCurrentReportingStatus_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityCurrentReportingStatus_lbl" xml:lang="en-US">Entity Current Reporting Status</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityInteractiveDataCurrent" xlink:label="dei_EntityInteractiveDataCurrent" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityInteractiveDataCurrent" xlink:to="dei_EntityInteractiveDataCurrent_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityInteractiveDataCurrent_lbl" xml:lang="en-US">Entity Interactive Data Current</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityFilerCategory" xlink:label="dei_EntityFilerCategory" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityFilerCategory" xlink:to="dei_EntityFilerCategory_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityFilerCategory_lbl" xml:lang="en-US">Entity Filer Category</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntitySmallBusiness" xlink:label="dei_EntitySmallBusiness" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntitySmallBusiness" xlink:to="dei_EntitySmallBusiness_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntitySmallBusiness_lbl" xml:lang="en-US">Entity Small Business</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityEmergingGrowthCompany" xlink:label="dei_EntityEmergingGrowthCompany" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityEmergingGrowthCompany" xlink:to="dei_EntityEmergingGrowthCompany_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityEmergingGrowthCompany_lbl" xml:lang="en-US">Entity Emerging Growth Company</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityExTransitionPeriod" xlink:label="dei_EntityExTransitionPeriod" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityExTransitionPeriod" xlink:to="dei_EntityExTransitionPeriod_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityExTransitionPeriod_lbl" xml:lang="en-US">Elected Not To Use the Extended Transition Period</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_DocumentAccountingStandard" xlink:label="dei_DocumentAccountingStandard" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_DocumentAccountingStandard" xlink:to="dei_DocumentAccountingStandard_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_DocumentAccountingStandard_lbl" xml:lang="en-US">Document Accounting Standard</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_OtherReportingStandardItemNumber" xlink:label="dei_OtherReportingStandardItemNumber" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_OtherReportingStandardItemNumber" xlink:to="dei_OtherReportingStandardItemNumber_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_OtherReportingStandardItemNumber_lbl" xml:lang="en-US">Other Reporting Standard Item Number</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityShellCompany" xlink:label="dei_EntityShellCompany" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityShellCompany" xlink:to="dei_EntityShellCompany_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityShellCompany_lbl" xml:lang="en-US">Entity Shell Company</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityPublicFloat" xlink:label="dei_EntityPublicFloat" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityPublicFloat" xlink:to="dei_EntityPublicFloat_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityPublicFloat_lbl" xml:lang="en-US">Entity Public Float</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityBankruptcyProceedingsReportingCurrent" xlink:label="dei_EntityBankruptcyProceedingsReportingCurrent" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityBankruptcyProceedingsReportingCurrent" xlink:to="dei_EntityBankruptcyProceedingsReportingCurrent_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityBankruptcyProceedingsReportingCurrent_lbl" xml:lang="en-US">Entity Bankruptcy Proceedings, Reporting Current</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityCommonStockSharesOutstanding" xlink:label="dei_EntityCommonStockSharesOutstanding" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityCommonStockSharesOutstanding" xlink:to="dei_EntityCommonStockSharesOutstanding_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityCommonStockSharesOutstanding_lbl" xml:lang="en-US">Entity Common Stock, Shares Outstanding</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_DocumentsIncorporatedByReferenceTextBlock" xlink:label="dei_DocumentsIncorporatedByReferenceTextBlock" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_DocumentsIncorporatedByReferenceTextBlock" xlink:to="dei_DocumentsIncorporatedByReferenceTextBlock_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_DocumentsIncorporatedByReferenceTextBlock_lbl" xml:lang="en-US">Documents Incorporated by Reference [Text Block]</link:label>
    </link:labelLink>
</link:linkbase>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.PRE
<SEQUENCE>11
<FILENAME>mbot-20230518_pre.xml
<DESCRIPTION>XBRL PRESENTATION FILE
<TEXT>
<XBRL>
<?xml version="1.0" encoding="US-ASCII" standalone="no"?>
    <!-- Field: Doc-Info; Name: Generator; Value: GoFiler Complete; Version: 5.18b -->
    <!-- Field: Doc-Info; Name: VendorURI; Value: https://www.novaworks.com -->
    <!-- Field: Doc-Info; Name: Status; Value: 0x00000000 -->
<link:linkbase xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:xbrli="http://www.xbrl.org/2003/instance" xsi:schemaLocation="http://www.xbrl.org/2003/linkbase http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd">
    <link:roleRef roleURI="http://microbotmedical.com/role/Cover" xlink:href="mbot-20230518.xsd#Cover" xlink:type="simple" />
    <link:presentationLink xlink:type="extended" xlink:role="http://microbotmedical.com/role/Cover" xlink:title="00000001 - Document - Cover">
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_CoverAbstract" xlink:label="loc_deiCoverAbstract" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_DocumentType" xlink:label="loc_deiDocumentType" />
      <link:presentationArc order="0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiDocumentType" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_AmendmentFlag" xlink:label="loc_deiAmendmentFlag" />
      <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiAmendmentFlag" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_AmendmentDescription" xlink:label="loc_deiAmendmentDescription" />
      <link:presentationArc order="20" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiAmendmentDescription" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_DocumentRegistrationStatement" xlink:label="loc_deiDocumentRegistrationStatement" />
      <link:presentationArc order="30" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiDocumentRegistrationStatement" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_DocumentAnnualReport" xlink:label="loc_deiDocumentAnnualReport" />
      <link:presentationArc order="40" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiDocumentAnnualReport" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_DocumentQuarterlyReport" xlink:label="loc_deiDocumentQuarterlyReport" />
      <link:presentationArc order="50" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiDocumentQuarterlyReport" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_DocumentTransitionReport" xlink:label="loc_deiDocumentTransitionReport" />
      <link:presentationArc order="60" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiDocumentTransitionReport" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_DocumentShellCompanyReport" xlink:label="loc_deiDocumentShellCompanyReport" />
      <link:presentationArc order="70" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiDocumentShellCompanyReport" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_DocumentShellCompanyEventDate" xlink:label="loc_deiDocumentShellCompanyEventDate" />
      <link:presentationArc order="80" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiDocumentShellCompanyEventDate" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_DocumentPeriodStartDate" xlink:label="loc_deiDocumentPeriodStartDate" />
      <link:presentationArc order="90" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiDocumentPeriodStartDate" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_DocumentPeriodEndDate" xlink:label="loc_deiDocumentPeriodEndDate" />
      <link:presentationArc order="100" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiDocumentPeriodEndDate" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_DocumentFiscalPeriodFocus" xlink:label="loc_deiDocumentFiscalPeriodFocus" />
      <link:presentationArc order="110" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiDocumentFiscalPeriodFocus" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_DocumentFiscalYearFocus" xlink:label="loc_deiDocumentFiscalYearFocus" />
      <link:presentationArc order="120" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiDocumentFiscalYearFocus" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_CurrentFiscalYearEndDate" xlink:label="loc_deiCurrentFiscalYearEndDate" />
      <link:presentationArc order="130" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiCurrentFiscalYearEndDate" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityFileNumber" xlink:label="loc_deiEntityFileNumber" />
      <link:presentationArc order="140" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiEntityFileNumber" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityRegistrantName" xlink:label="loc_deiEntityRegistrantName" />
      <link:presentationArc order="150" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiEntityRegistrantName" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityCentralIndexKey" xlink:label="loc_deiEntityCentralIndexKey" />
      <link:presentationArc order="160" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiEntityCentralIndexKey" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityPrimarySicNumber" xlink:label="loc_deiEntityPrimarySicNumber" />
      <link:presentationArc order="170" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiEntityPrimarySicNumber" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityTaxIdentificationNumber" xlink:label="loc_deiEntityTaxIdentificationNumber" />
      <link:presentationArc order="180" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiEntityTaxIdentificationNumber" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityIncorporationStateCountryCode" xlink:label="loc_deiEntityIncorporationStateCountryCode" />
      <link:presentationArc order="190" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiEntityIncorporationStateCountryCode" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityAddressAddressLine1" xlink:label="loc_deiEntityAddressAddressLine1" />
      <link:presentationArc order="200" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiEntityAddressAddressLine1" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityAddressAddressLine2" xlink:label="loc_deiEntityAddressAddressLine2" />
      <link:presentationArc order="210" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiEntityAddressAddressLine2" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityAddressAddressLine3" xlink:label="loc_deiEntityAddressAddressLine3" />
      <link:presentationArc order="220" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiEntityAddressAddressLine3" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityAddressCityOrTown" xlink:label="loc_deiEntityAddressCityOrTown" />
      <link:presentationArc order="230" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiEntityAddressCityOrTown" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityAddressStateOrProvince" xlink:label="loc_deiEntityAddressStateOrProvince" />
      <link:presentationArc order="240" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiEntityAddressStateOrProvince" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityAddressCountry" xlink:label="loc_deiEntityAddressCountry" />
      <link:presentationArc order="250" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiEntityAddressCountry" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityAddressPostalZipCode" xlink:label="loc_deiEntityAddressPostalZipCode" />
      <link:presentationArc order="260" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiEntityAddressPostalZipCode" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_CountryRegion" xlink:label="loc_deiCountryRegion" />
      <link:presentationArc order="270" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiCountryRegion" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_CityAreaCode" xlink:label="loc_deiCityAreaCode" />
      <link:presentationArc order="280" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiCityAreaCode" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_LocalPhoneNumber" xlink:label="loc_deiLocalPhoneNumber" />
      <link:presentationArc order="290" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiLocalPhoneNumber" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_Extension" xlink:label="loc_deiExtension" />
      <link:presentationArc order="300" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiExtension" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_WrittenCommunications" xlink:label="loc_deiWrittenCommunications" />
      <link:presentationArc order="310" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiWrittenCommunications" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_SolicitingMaterial" xlink:label="loc_deiSolicitingMaterial" />
      <link:presentationArc order="320" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiSolicitingMaterial" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_PreCommencementTenderOffer" xlink:label="loc_deiPreCommencementTenderOffer" />
      <link:presentationArc order="330" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiPreCommencementTenderOffer" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_PreCommencementIssuerTenderOffer" xlink:label="loc_deiPreCommencementIssuerTenderOffer" />
      <link:presentationArc order="340" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiPreCommencementIssuerTenderOffer" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_Security12bTitle" xlink:label="loc_deiSecurity12bTitle" />
      <link:presentationArc order="350" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiSecurity12bTitle" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_NoTradingSymbolFlag" xlink:label="loc_deiNoTradingSymbolFlag" />
      <link:presentationArc order="360" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiNoTradingSymbolFlag" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_TradingSymbol" xlink:label="loc_deiTradingSymbol" />
      <link:presentationArc order="370" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiTradingSymbol" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_SecurityExchangeName" xlink:label="loc_deiSecurityExchangeName" />
      <link:presentationArc order="380" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiSecurityExchangeName" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_Security12gTitle" xlink:label="loc_deiSecurity12gTitle" />
      <link:presentationArc order="390" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiSecurity12gTitle" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_SecurityReportingObligation" xlink:label="loc_deiSecurityReportingObligation" />
      <link:presentationArc order="400" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiSecurityReportingObligation" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_AnnualInformationForm" xlink:label="loc_deiAnnualInformationForm" />
      <link:presentationArc order="410" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiAnnualInformationForm" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_AuditedAnnualFinancialStatements" xlink:label="loc_deiAuditedAnnualFinancialStatements" />
      <link:presentationArc order="420" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiAuditedAnnualFinancialStatements" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityWellKnownSeasonedIssuer" xlink:label="loc_deiEntityWellKnownSeasonedIssuer" />
      <link:presentationArc order="430" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiEntityWellKnownSeasonedIssuer" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityVoluntaryFilers" xlink:label="loc_deiEntityVoluntaryFilers" />
      <link:presentationArc order="440" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiEntityVoluntaryFilers" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityCurrentReportingStatus" xlink:label="loc_deiEntityCurrentReportingStatus" />
      <link:presentationArc order="450" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiEntityCurrentReportingStatus" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityInteractiveDataCurrent" xlink:label="loc_deiEntityInteractiveDataCurrent" />
      <link:presentationArc order="460" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiEntityInteractiveDataCurrent" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityFilerCategory" xlink:label="loc_deiEntityFilerCategory" />
      <link:presentationArc order="470" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiEntityFilerCategory" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntitySmallBusiness" xlink:label="loc_deiEntitySmallBusiness" />
      <link:presentationArc order="480" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiEntitySmallBusiness" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityEmergingGrowthCompany" xlink:label="loc_deiEntityEmergingGrowthCompany" />
      <link:presentationArc order="490" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiEntityEmergingGrowthCompany" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityExTransitionPeriod" xlink:label="loc_deiEntityExTransitionPeriod" />
      <link:presentationArc order="500" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiEntityExTransitionPeriod" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_DocumentAccountingStandard" xlink:label="loc_deiDocumentAccountingStandard" />
      <link:presentationArc order="510" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiDocumentAccountingStandard" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_OtherReportingStandardItemNumber" xlink:label="loc_deiOtherReportingStandardItemNumber" />
      <link:presentationArc order="520" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiOtherReportingStandardItemNumber" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityShellCompany" xlink:label="loc_deiEntityShellCompany" />
      <link:presentationArc order="530" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiEntityShellCompany" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityPublicFloat" xlink:label="loc_deiEntityPublicFloat" />
      <link:presentationArc order="540" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiEntityPublicFloat" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityBankruptcyProceedingsReportingCurrent" xlink:label="loc_deiEntityBankruptcyProceedingsReportingCurrent" />
      <link:presentationArc order="550" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiEntityBankruptcyProceedingsReportingCurrent" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityCommonStockSharesOutstanding" xlink:label="loc_deiEntityCommonStockSharesOutstanding" />
      <link:presentationArc order="560" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiEntityCommonStockSharesOutstanding" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_DocumentsIncorporatedByReferenceTextBlock" xlink:label="loc_deiDocumentsIncorporatedByReferenceTextBlock" />
      <link:presentationArc order="570" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiDocumentsIncorporatedByReferenceTextBlock" xlink:type="arc" />
    </link:presentationLink>
</link:linkbase>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>12
<FILENAME>R1.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.23.1</span><table class="report" border="0" cellspacing="2" id="idm140019049323232">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Cover<br></strong></div></th>
<th class="th"><div>May 18, 2023</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_CoverAbstract', window );"><strong>Cover [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_DocumentType', window );">Document Type</a></td>
<td class="text">8-K<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_AmendmentFlag', window );">Amendment Flag</a></td>
<td class="text">false<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_DocumentPeriodEndDate', window );">Document Period End Date</a></td>
<td class="text">May 18,  2023<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityFileNumber', window );">Entity File Number</a></td>
<td class="text">000-19871<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityRegistrantName', window );">Entity Registrant Name</a></td>
<td class="text">MICROBOT
MEDICAL INC.<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityCentralIndexKey', window );">Entity Central Index Key</a></td>
<td class="text">0000883975<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityTaxIdentificationNumber', window );">Entity Tax Identification Number</a></td>
<td class="text">94-3078125<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityIncorporationStateCountryCode', window );">Entity Incorporation, State or Country Code</a></td>
<td class="text">DE<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityAddressAddressLine1', window );">Entity Address, Address Line One</a></td>
<td class="text">25
Recreation Park Drive<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityAddressAddressLine2', window );">Entity Address, Address Line Two</a></td>
<td class="text">Unit 108<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityAddressCityOrTown', window );">Entity Address, City or Town</a></td>
<td class="text">Hingham<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityAddressStateOrProvince', window );">Entity Address, State or Province</a></td>
<td class="text">MA<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityAddressPostalZipCode', window );">Entity Address, Postal Zip Code</a></td>
<td class="text">02043<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_CityAreaCode', window );">City Area Code</a></td>
<td class="text">(781)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_LocalPhoneNumber', window );">Local Phone Number</a></td>
<td class="text">875-3605<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_WrittenCommunications', window );">Written Communications</a></td>
<td class="text">false<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_SolicitingMaterial', window );">Soliciting Material</a></td>
<td class="text">false<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_PreCommencementTenderOffer', window );">Pre-commencement Tender Offer</a></td>
<td class="text">false<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_PreCommencementIssuerTenderOffer', window );">Pre-commencement Issuer Tender Offer</a></td>
<td class="text">false<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_Security12bTitle', window );">Title of 12(b) Security</a></td>
<td class="text">Common Stock, $0.01 par
    value<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_TradingSymbol', window );">Trading Symbol</a></td>
<td class="text">MBOT<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_SecurityExchangeName', window );">Security Exchange Name</a></td>
<td class="text">NASDAQ<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityEmergingGrowthCompany', window );">Entity Emerging Growth Company</a></td>
<td class="text">false<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_AmendmentFlag">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true when the XBRL content amends previously-filed or accepted submission.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_AmendmentFlag</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_CityAreaCode">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Area code of city</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_CityAreaCode</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_CoverAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Cover page.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_CoverAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentPeriodEndDate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>For the EDGAR submission types of Form 8-K: the date of the report, the date of the earliest event reported; for the EDGAR submission types of Form N-1A: the filing date; for all other submission types: the end of the reporting or transition period.  The format of the date is YYYY-MM-DD.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentPeriodEndDate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:dateItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentType">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The type of document being provided (such as 10-K, 10-Q, 485BPOS, etc). The document type is limited to the same value as the supporting SEC submission type, or the word 'Other'.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentType</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:submissionTypeItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityAddressAddressLine1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Address Line 1 such as Attn, Building Name, Street Name</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityAddressAddressLine1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityAddressAddressLine2">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Address Line 2 such as Street or Suite number</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityAddressAddressLine2</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityAddressCityOrTown">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Name of the City or Town</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityAddressCityOrTown</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityAddressPostalZipCode">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Code for the postal or zip code</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityAddressPostalZipCode</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityAddressStateOrProvince">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Name of the state or province.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityAddressStateOrProvince</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:stateOrProvinceItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityCentralIndexKey">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>A unique 10-digit SEC-issued value to identify entities that have filed disclosures with the SEC. It is commonly abbreviated as CIK.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityCentralIndexKey</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:centralIndexKeyItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityEmergingGrowthCompany">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Indicate if registrant meets the emerging growth company criteria.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityEmergingGrowthCompany</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityFileNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Commission file number. The field allows up to 17 characters. The prefix may contain 1-3 digits, the sequence number may contain 1-8 digits, the optional suffix may contain 1-4 characters, and the fields are separated with a hyphen.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityFileNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:fileNumberItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityIncorporationStateCountryCode">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Two-character EDGAR code representing the state or country of incorporation.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityIncorporationStateCountryCode</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:edgarStateCountryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityRegistrantName">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The exact name of the entity filing the report as specified in its charter, which is required by forms filed with the SEC.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityRegistrantName</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityTaxIdentificationNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The Tax Identification Number (TIN), also known as an Employer Identification Number (EIN), is a unique 9-digit value assigned by the IRS.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityTaxIdentificationNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:employerIdItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_LocalPhoneNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Local phone number for entity.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_LocalPhoneNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_PreCommencementIssuerTenderOffer">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 13e<br> -Subsection 4c<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_PreCommencementIssuerTenderOffer</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_PreCommencementTenderOffer">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 14d<br> -Subsection 2b<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_PreCommencementTenderOffer</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_Security12bTitle">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Title of a 12(b) registered security.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_Security12bTitle</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:securityTitleItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_SecurityExchangeName">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Name of the Exchange on which a security is registered.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection d1-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_SecurityExchangeName</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:edgarExchangeCodeItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_SolicitingMaterial">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as soliciting material pursuant to Rule 14a-12 under the Exchange Act.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Section 14a<br> -Number 240<br> -Subsection 12<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_SolicitingMaterial</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_TradingSymbol">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Trading symbol of an instrument as listed on an exchange.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_TradingSymbol</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:tradingSymbolItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_WrittenCommunications">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as written communications pursuant to Rule 425 under the Securities Act.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Securities Act<br> -Number 230<br> -Section 425<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_WrittenCommunications</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>13
<FILENAME>form8-k_htm.xml
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<XML>
<?xml version="1.0" encoding="utf-8"?>
<xbrl
  xmlns="http://www.xbrl.org/2003/instance"
  xmlns:dei="http://xbrl.sec.gov/dei/2022"
  xmlns:iso4217="http://www.xbrl.org/2003/iso4217"
  xmlns:link="http://www.xbrl.org/2003/linkbase"
  xmlns:xlink="http://www.w3.org/1999/xlink">
    <link:schemaRef xlink:href="mbot-20230518.xsd" xlink:type="simple"/>
    <context id="From2023-05-18to2023-05-18">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000883975</identifier>
        </entity>
        <period>
            <startDate>2023-05-18</startDate>
            <endDate>2023-05-18</endDate>
        </period>
    </context>
    <unit id="USD">
        <measure>iso4217:USD</measure>
    </unit>
    <unit id="Shares">
        <measure>shares</measure>
    </unit>
    <unit id="USDPShares">
        <divide>
            <unitNumerator>
                <measure>iso4217:USD</measure>
            </unitNumerator>
            <unitDenominator>
                <measure>shares</measure>
            </unitDenominator>
        </divide>
    </unit>
    <dei:EntityCentralIndexKey contextRef="From2023-05-18to2023-05-18">0000883975</dei:EntityCentralIndexKey>
    <dei:AmendmentFlag contextRef="From2023-05-18to2023-05-18">false</dei:AmendmentFlag>
    <dei:DocumentType contextRef="From2023-05-18to2023-05-18">8-K</dei:DocumentType>
    <dei:DocumentPeriodEndDate contextRef="From2023-05-18to2023-05-18">2023-05-18</dei:DocumentPeriodEndDate>
    <dei:EntityRegistrantName contextRef="From2023-05-18to2023-05-18">MICROBOT MEDICAL INC.</dei:EntityRegistrantName>
    <dei:EntityIncorporationStateCountryCode contextRef="From2023-05-18to2023-05-18">DE</dei:EntityIncorporationStateCountryCode>
    <dei:EntityFileNumber contextRef="From2023-05-18to2023-05-18">000-19871</dei:EntityFileNumber>
    <dei:EntityTaxIdentificationNumber contextRef="From2023-05-18to2023-05-18">94-3078125</dei:EntityTaxIdentificationNumber>
    <dei:EntityAddressAddressLine1 contextRef="From2023-05-18to2023-05-18">25 Recreation Park Drive</dei:EntityAddressAddressLine1>
    <dei:EntityAddressAddressLine2 contextRef="From2023-05-18to2023-05-18">Unit 108</dei:EntityAddressAddressLine2>
    <dei:EntityAddressCityOrTown contextRef="From2023-05-18to2023-05-18">Hingham</dei:EntityAddressCityOrTown>
    <dei:EntityAddressStateOrProvince contextRef="From2023-05-18to2023-05-18">MA</dei:EntityAddressStateOrProvince>
    <dei:EntityAddressPostalZipCode contextRef="From2023-05-18to2023-05-18">02043</dei:EntityAddressPostalZipCode>
    <dei:CityAreaCode contextRef="From2023-05-18to2023-05-18">(781)</dei:CityAreaCode>
    <dei:LocalPhoneNumber contextRef="From2023-05-18to2023-05-18">875-3605</dei:LocalPhoneNumber>
    <dei:WrittenCommunications contextRef="From2023-05-18to2023-05-18">false</dei:WrittenCommunications>
    <dei:SolicitingMaterial contextRef="From2023-05-18to2023-05-18">false</dei:SolicitingMaterial>
    <dei:PreCommencementTenderOffer contextRef="From2023-05-18to2023-05-18">false</dei:PreCommencementTenderOffer>
    <dei:PreCommencementIssuerTenderOffer contextRef="From2023-05-18to2023-05-18">false</dei:PreCommencementIssuerTenderOffer>
    <dei:Security12bTitle contextRef="From2023-05-18to2023-05-18">Common Stock, $0.01 par     value</dei:Security12bTitle>
    <dei:TradingSymbol contextRef="From2023-05-18to2023-05-18">MBOT</dei:TradingSymbol>
    <dei:SecurityExchangeName contextRef="From2023-05-18to2023-05-18">NASDAQ</dei:SecurityExchangeName>
    <dei:EntityEmergingGrowthCompany contextRef="From2023-05-18to2023-05-18">false</dei:EntityEmergingGrowthCompany>
</xbrl>
</XML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EXCEL
<SEQUENCE>14
<FILENAME>Financial_Report.xlsx
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
begin 644 Financial_Report.xlsx
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MW&,EC'%BM/XU@LD/['X 4$L#!!0    ( ,E#ME:JQ"(6,P$  "("   /
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M              "  <P!  !X;"]T:&5M92]T:&5M93$N>&UL4$L! A0#%
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M+W=O<FMB;V]K+GAM;%!+ 0(4 Q0    ( ,E#ME8D'INBK0   /@!   :
M          "  <@1  !X;"]?<F5L<R]W;W)K8F]O:RYX;6PN<F5L<U!+ 0(4
M Q0    ( ,E#ME9ED'F2&0$  ,\#   3              "  :T2  !;0V]N
E=&5N=%]4>7!E<UTN>&UL4$L%!@     )  D /@(  /<3      $!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>15
<FILENAME>Show.js
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
// Edgar(tm) Renderer was created by staff of the U.S. Securities and Exchange Commission.  Data and content created by government employees within the scope of their employment are not subject to domestic copyright protection. 17 U.S.C. 105.
var Show={};Show.LastAR=null,Show.showAR=function(a,r,w){if(Show.LastAR)Show.hideAR();var e=a;while(e&&e.nodeName!='TABLE')e=e.nextSibling;if(!e||e.nodeName!='TABLE'){var ref=((window)?w.document:document).getElementById(r);if(ref){e=ref.cloneNode(!0);
e.removeAttribute('id');a.parentNode.appendChild(e)}}
if(e)e.style.display='block';Show.LastAR=e};Show.hideAR=function(){Show.LastAR.style.display='none'};Show.toggleNext=function(a){var e=a;while(e.nodeName!='DIV')e=e.nextSibling;if(!e.style){}else if(!e.style.display){}else{var d,p_;if(e.style.display=='none'){d='block';p='-'}else{d='none';p='+'}
e.style.display=d;if(a.textContent){a.textContent=p+a.textContent.substring(1)}else{a.innerText=p+a.innerText.substring(1)}}}
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>16
<FILENAME>report.css
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
/* Updated 2009-11-04 */
/* v2.2.0.24 */

/* DefRef Styles */
..report table.authRefData{
	background-color: #def;
	border: 2px solid #2F4497;
	font-size: 1em;
	position: absolute;
}

..report table.authRefData a {
	display: block;
	font-weight: bold;
}

..report table.authRefData p {
	margin-top: 0px;
}

..report table.authRefData .hide {
	background-color: #2F4497;
	padding: 1px 3px 0px 0px;
	text-align: right;
}

..report table.authRefData .hide a:hover {
	background-color: #2F4497;
}

..report table.authRefData .body {
	height: 150px;
	overflow: auto;
	width: 400px;
}

..report table.authRefData table{
	font-size: 1em;
}

/* Report Styles */
..pl a, .pl a:visited {
	color: black;
	text-decoration: none;
}

/* table */
..report {
	background-color: white;
	border: 2px solid #acf;
	clear: both;
	color: black;
	font: normal 8pt Helvetica, Arial, san-serif;
	margin-bottom: 2em;
}

..report hr {
	border: 1px solid #acf;
}

/* Top labels */
..report th {
	background-color: #acf;
	color: black;
	font-weight: bold;
	text-align: center;
}

..report th.void	{
	background-color: transparent;
	color: #000000;
	font: bold 10pt Helvetica, Arial, san-serif;
	text-align: left;
}

..report .pl {
	text-align: left;
	vertical-align: top;
	white-space: normal;
	width: 200px;
	white-space: normal; /* word-wrap: break-word; */
}

..report td.pl a.a {
	cursor: pointer;
	display: block;
	width: 200px;
	overflow: hidden;
}

..report td.pl div.a {
	width: 200px;
}

..report td.pl a:hover {
	background-color: #ffc;
}

/* Header rows... */
..report tr.rh {
	background-color: #acf;
	color: black;
	font-weight: bold;
}

/* Calendars... */
..report .rc {
	background-color: #f0f0f0;
}

/* Even rows... */
..report .re, .report .reu {
	background-color: #def;
}

..report .reu td {
	border-bottom: 1px solid black;
}

/* Odd rows... */
..report .ro, .report .rou {
	background-color: white;
}

..report .rou td {
	border-bottom: 1px solid black;
}

..report .rou table td, .report .reu table td {
	border-bottom: 0px solid black;
}

/* styles for footnote marker */
..report .fn {
	white-space: nowrap;
}

/* styles for numeric types */
..report .num, .report .nump {
	text-align: right;
	white-space: nowrap;
}

..report .nump {
	padding-left: 2em;
}

..report .nump {
	padding: 0px 0.4em 0px 2em;
}

/* styles for text types */
..report .text {
	text-align: left;
	white-space: normal;
}

..report .text .big {
	margin-bottom: 1em;
	width: 17em;
}

..report .text .more {
	display: none;
}

..report .text .note {
	font-style: italic;
	font-weight: bold;
}

..report .text .small {
	width: 10em;
}

..report sup {
	font-style: italic;
}

..report .outerFootnotes {
	font-size: 1em;
}
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>17
<FILENAME>FilingSummary.xml
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<XML>
<?xml version='1.0' encoding='utf-8'?>
<FilingSummary>
  <Version>3.23.1</Version>
  <ProcessingTime/>
  <ReportFormat>html</ReportFormat>
  <ContextCount>1</ContextCount>
  <ElementCount>23</ElementCount>
  <EntityCount>1</EntityCount>
  <FootnotesReported>false</FootnotesReported>
  <SegmentCount>0</SegmentCount>
  <ScenarioCount>0</ScenarioCount>
  <TuplesReported>false</TuplesReported>
  <UnitCount>3</UnitCount>
  <MyReports>
    <Report instance="form8-k.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R1.htm</HtmlFileName>
      <LongName>00000001 - Document - Cover</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://microbotmedical.com/role/Cover</Role>
      <ShortName>Cover</ShortName>
      <MenuCategory>Cover</MenuCategory>
      <Position>1</Position>
    </Report>
    <Report>
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <LongName>All Reports</LongName>
      <ReportType>Book</ReportType>
      <ShortName>All Reports</ShortName>
    </Report>
  </MyReports>
  <InputFiles>
    <File doctype="8-K" original="form8-k.htm">form8-k.htm</File>
    <File>ex10-1.htm</File>
    <File>ex10-2.htm</File>
    <File>ex10-3.htm</File>
    <File>ex10-4.htm</File>
    <File>ex99-1.htm</File>
    <File>mbot-20230518.xsd</File>
    <File>mbot-20230518_lab.xml</File>
    <File>mbot-20230518_pre.xml</File>
  </InputFiles>
  <SupplementalFiles/>
  <BaseTaxonomies>
    <BaseTaxonomy items="23">http://xbrl.sec.gov/dei/2022</BaseTaxonomy>
  </BaseTaxonomies>
  <HasPresentationLinkbase>true</HasPresentationLinkbase>
  <HasCalculationLinkbase>false</HasCalculationLinkbase>
</FilingSummary>
</XML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>JSON
<SEQUENCE>19
<FILENAME>MetaLinks.json
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
{
 "instance": {
  "form8-k.htm": {
   "axisCustom": 0,
   "axisStandard": 0,
   "baseTaxonomies": {
    "http://xbrl.sec.gov/dei/2022": 23
   },
   "contextCount": 1,
   "dts": {
    "inline": {
     "local": [
      "form8-k.htm"
     ]
    },
    "labelLink": {
     "local": [
      "mbot-20230518_lab.xml"
     ]
    },
    "presentationLink": {
     "local": [
      "mbot-20230518_pre.xml"
     ]
    },
    "schema": {
     "local": [
      "mbot-20230518.xsd"
     ],
     "remote": [
      "http://www.xbrl.org/2003/xbrl-instance-2003-12-31.xsd",
      "http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd",
      "http://www.xbrl.org/2003/xl-2003-12-31.xsd",
      "http://www.xbrl.org/2003/xlink-2003-12-31.xsd",
      "http://www.xbrl.org/2005/xbrldt-2005.xsd",
      "http://www.xbrl.org/2006/ref-2006-02-27.xsd",
      "http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd",
      "http://www.xbrl.org/lrr/role/net-2009-12-16.xsd",
      "https://www.xbrl.org/2020/extensible-enumerations-2.0.xsd",
      "https://www.xbrl.org/dtr/type/2020-01-21/types.xsd",
      "https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd",
      "https://xbrl.fasb.org/srt/2022/elts/srt-roles-2022.xsd",
      "https://xbrl.fasb.org/srt/2022/elts/srt-types-2022.xsd",
      "https://xbrl.fasb.org/srt/2022q3/srt-sup-2022q3.xsd",
      "https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd",
      "https://xbrl.fasb.org/us-gaap/2022/elts/us-roles-2022.xsd",
      "https://xbrl.fasb.org/us-gaap/2022/elts/us-types-2022.xsd",
      "https://xbrl.fasb.org/us-gaap/2022q3/us-gaap-sup-2022q3.xsd",
      "https://xbrl.sec.gov/country/2022/country-2022.xsd",
      "https://xbrl.sec.gov/dei/2022/dei-2022.xsd"
     ]
    }
   },
   "elementCount": 59,
   "entityCount": 1,
   "hidden": {
    "http://xbrl.sec.gov/dei/2022": 2,
    "total": 2
   },
   "keyCustom": 0,
   "keyStandard": 23,
   "memberCustom": 0,
   "memberStandard": 0,
   "nsprefix": "MBOT",
   "nsuri": "http://microbotmedical.com/20230518",
   "report": {
    "R1": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "b",
       "span",
       "p",
       "body",
       "html"
      ],
      "baseRef": "form8-k.htm",
      "contextRef": "From2023-05-18to2023-05-18",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "dei:DocumentType",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "document",
     "isDefault": "true",
     "longName": "00000001 - Document - Cover",
     "menuCat": "Cover",
     "order": "1",
     "role": "http://microbotmedical.com/role/Cover",
     "shortName": "Cover",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "b",
       "span",
       "p",
       "body",
       "html"
      ],
      "baseRef": "form8-k.htm",
      "contextRef": "From2023-05-18to2023-05-18",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "dei:DocumentType",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    }
   },
   "segmentCount": 0,
   "tag": {
    "dei_AmendmentDescription": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Description of changes contained within amended document.",
        "label": "Amendment Description"
       }
      }
     },
     "localname": "AmendmentDescription",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://microbotmedical.com/role/Cover"
     ],
     "xbrltype": "stringItemType"
    },
    "dei_AmendmentFlag": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Boolean flag that is true when the XBRL content amends previously-filed or accepted submission.",
        "label": "Amendment Flag"
       }
      }
     },
     "localname": "AmendmentFlag",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://microbotmedical.com/role/Cover"
     ],
     "xbrltype": "booleanItemType"
    },
    "dei_AnnualInformationForm": {
     "auth_ref": [
      "r14"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Boolean flag with value true on a form if it is an annual report containing an annual information form.",
        "label": "Annual Information Form"
       }
      }
     },
     "localname": "AnnualInformationForm",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://microbotmedical.com/role/Cover"
     ],
     "xbrltype": "booleanItemType"
    },
    "dei_AuditedAnnualFinancialStatements": {
     "auth_ref": [
      "r14"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Boolean flag with value true on a form if it is an annual report containing audited financial statements.",
        "label": "Audited Annual Financial Statements"
       }
      }
     },
     "localname": "AuditedAnnualFinancialStatements",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://microbotmedical.com/role/Cover"
     ],
     "xbrltype": "booleanItemType"
    },
    "dei_CityAreaCode": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Area code of city",
        "label": "City Area Code"
       }
      }
     },
     "localname": "CityAreaCode",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://microbotmedical.com/role/Cover"
     ],
     "xbrltype": "normalizedStringItemType"
    },
    "dei_CountryRegion": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Region code of country",
        "label": "Country Region"
       }
      }
     },
     "localname": "CountryRegion",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://microbotmedical.com/role/Cover"
     ],
     "xbrltype": "normalizedStringItemType"
    },
    "dei_CoverAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Cover page.",
        "label": "Cover [Abstract]"
       }
      }
     },
     "localname": "CoverAbstract",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "xbrltype": "stringItemType"
    },
    "dei_CurrentFiscalYearEndDate": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "End date of current fiscal year in the format --MM-DD.",
        "label": "Current Fiscal Year End Date"
       }
      }
     },
     "localname": "CurrentFiscalYearEndDate",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://microbotmedical.com/role/Cover"
     ],
     "xbrltype": "gMonthDayItemType"
    },
    "dei_DocumentAccountingStandard": {
     "auth_ref": [
      "r13"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The basis of accounting the registrant has used to prepare the financial statements included in this filing This can either be 'U.S. GAAP', 'International Financial Reporting Standards', or 'Other'.",
        "label": "Document Accounting Standard"
       }
      }
     },
     "localname": "DocumentAccountingStandard",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://microbotmedical.com/role/Cover"
     ],
     "xbrltype": "accountingStandardItemType"
    },
    "dei_DocumentAnnualReport": {
     "auth_ref": [
      "r11",
      "r13",
      "r14"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Boolean flag that is true only for a form used as an annual report.",
        "label": "Document Annual Report"
       }
      }
     },
     "localname": "DocumentAnnualReport",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://microbotmedical.com/role/Cover"
     ],
     "xbrltype": "booleanItemType"
    },
    "dei_DocumentFiscalPeriodFocus": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Fiscal period values are FY, Q1, Q2, and Q3.  1st, 2nd and 3rd quarter 10-Q or 10-QT statements have value Q1, Q2, and Q3 respectively, with 10-K, 10-KT or other fiscal year statements having FY.",
        "label": "Document Fiscal Period Focus"
       }
      }
     },
     "localname": "DocumentFiscalPeriodFocus",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://microbotmedical.com/role/Cover"
     ],
     "xbrltype": "fiscalPeriodItemType"
    },
    "dei_DocumentFiscalYearFocus": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "This is focus fiscal year of the document report in YYYY format. For a 2006 annual report, which may also provide financial information from prior periods, fiscal 2006 should be given as the fiscal year focus. Example: 2006.",
        "label": "Document Fiscal Year Focus"
       }
      }
     },
     "localname": "DocumentFiscalYearFocus",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://microbotmedical.com/role/Cover"
     ],
     "xbrltype": "gYearItemType"
    },
    "dei_DocumentPeriodEndDate": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "For the EDGAR submission types of Form 8-K: the date of the report, the date of the earliest event reported; for the EDGAR submission types of Form N-1A: the filing date; for all other submission types: the end of the reporting or transition period.  The format of the date is YYYY-MM-DD.",
        "label": "Document Period End Date"
       }
      }
     },
     "localname": "DocumentPeriodEndDate",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://microbotmedical.com/role/Cover"
     ],
     "xbrltype": "dateItemType"
    },
    "dei_DocumentPeriodStartDate": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The start date of the period covered in the document, in YYYY-MM-DD format.",
        "label": "Document Period Start Date"
       }
      }
     },
     "localname": "DocumentPeriodStartDate",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://microbotmedical.com/role/Cover"
     ],
     "xbrltype": "dateItemType"
    },
    "dei_DocumentQuarterlyReport": {
     "auth_ref": [
      "r12"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Boolean flag that is true only for a form used as an quarterly report.",
        "label": "Document Quarterly Report"
       }
      }
     },
     "localname": "DocumentQuarterlyReport",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://microbotmedical.com/role/Cover"
     ],
     "xbrltype": "booleanItemType"
    },
    "dei_DocumentRegistrationStatement": {
     "auth_ref": [
      "r0"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Boolean flag that is true only for a form used as a registration statement.",
        "label": "Document Registration Statement"
       }
      }
     },
     "localname": "DocumentRegistrationStatement",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://microbotmedical.com/role/Cover"
     ],
     "xbrltype": "booleanItemType"
    },
    "dei_DocumentShellCompanyEventDate": {
     "auth_ref": [
      "r13"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Date of event requiring a shell company report.",
        "label": "Document Shell Company Event Date"
       }
      }
     },
     "localname": "DocumentShellCompanyEventDate",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://microbotmedical.com/role/Cover"
     ],
     "xbrltype": "dateItemType"
    },
    "dei_DocumentShellCompanyReport": {
     "auth_ref": [
      "r13"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Boolean flag that is true for a Shell Company Report pursuant to section 13 or 15(d) of the Exchange Act.",
        "label": "Document Shell Company Report"
       }
      }
     },
     "localname": "DocumentShellCompanyReport",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://microbotmedical.com/role/Cover"
     ],
     "xbrltype": "booleanItemType"
    },
    "dei_DocumentTransitionReport": {
     "auth_ref": [
      "r15"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Boolean flag that is true only for a form used as a transition report.",
        "label": "Document Transition Report"
       }
      }
     },
     "localname": "DocumentTransitionReport",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://microbotmedical.com/role/Cover"
     ],
     "xbrltype": "booleanItemType"
    },
    "dei_DocumentType": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The type of document being provided (such as 10-K, 10-Q, 485BPOS, etc). The document type is limited to the same value as the supporting SEC submission type, or the word 'Other'.",
        "label": "Document Type"
       }
      }
     },
     "localname": "DocumentType",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://microbotmedical.com/role/Cover"
     ],
     "xbrltype": "submissionTypeItemType"
    },
    "dei_DocumentsIncorporatedByReferenceTextBlock": {
     "auth_ref": [
      "r3"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Documents incorporated by reference.",
        "label": "Documents Incorporated by Reference [Text Block]"
       }
      }
     },
     "localname": "DocumentsIncorporatedByReferenceTextBlock",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://microbotmedical.com/role/Cover"
     ],
     "xbrltype": "textBlockItemType"
    },
    "dei_EntityAddressAddressLine1": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Address Line 1 such as Attn, Building Name, Street Name",
        "label": "Entity Address, Address Line One"
       }
      }
     },
     "localname": "EntityAddressAddressLine1",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://microbotmedical.com/role/Cover"
     ],
     "xbrltype": "normalizedStringItemType"
    },
    "dei_EntityAddressAddressLine2": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Address Line 2 such as Street or Suite number",
        "label": "Entity Address, Address Line Two"
       }
      }
     },
     "localname": "EntityAddressAddressLine2",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://microbotmedical.com/role/Cover"
     ],
     "xbrltype": "normalizedStringItemType"
    },
    "dei_EntityAddressAddressLine3": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Address Line 3 such as an Office Park",
        "label": "Entity Address, Address Line Three"
       }
      }
     },
     "localname": "EntityAddressAddressLine3",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://microbotmedical.com/role/Cover"
     ],
     "xbrltype": "normalizedStringItemType"
    },
    "dei_EntityAddressCityOrTown": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Name of the City or Town",
        "label": "Entity Address, City or Town"
       }
      }
     },
     "localname": "EntityAddressCityOrTown",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://microbotmedical.com/role/Cover"
     ],
     "xbrltype": "normalizedStringItemType"
    },
    "dei_EntityAddressCountry": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "ISO 3166-1 alpha-2 country code.",
        "label": "Entity Address, Country"
       }
      }
     },
     "localname": "EntityAddressCountry",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://microbotmedical.com/role/Cover"
     ],
     "xbrltype": "countryCodeItemType"
    },
    "dei_EntityAddressPostalZipCode": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Code for the postal or zip code",
        "label": "Entity Address, Postal Zip Code"
       }
      }
     },
     "localname": "EntityAddressPostalZipCode",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://microbotmedical.com/role/Cover"
     ],
     "xbrltype": "normalizedStringItemType"
    },
    "dei_EntityAddressStateOrProvince": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Name of the state or province.",
        "label": "Entity Address, State or Province"
       }
      }
     },
     "localname": "EntityAddressStateOrProvince",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://microbotmedical.com/role/Cover"
     ],
     "xbrltype": "stateOrProvinceItemType"
    },
    "dei_EntityBankruptcyProceedingsReportingCurrent": {
     "auth_ref": [
      "r6"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "For registrants involved in bankruptcy proceedings during the preceding five years, the value Yes indicates that the registrant has filed all documents and reports required to be filed by Section 12, 13 or 15(d) of the Securities Exchange Act of 1934 subsequent to the distribution of securities under a plan confirmed by a court; the value No indicates the registrant has not.  Registrants not involved in bankruptcy proceedings during the preceding five years should not report this element.",
        "label": "Entity Bankruptcy Proceedings, Reporting Current"
       }
      }
     },
     "localname": "EntityBankruptcyProceedingsReportingCurrent",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://microbotmedical.com/role/Cover"
     ],
     "xbrltype": "booleanItemType"
    },
    "dei_EntityCentralIndexKey": {
     "auth_ref": [
      "r2"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "A unique 10-digit SEC-issued value to identify entities that have filed disclosures with the SEC. It is commonly abbreviated as CIK.",
        "label": "Entity Central Index Key"
       }
      }
     },
     "localname": "EntityCentralIndexKey",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://microbotmedical.com/role/Cover"
     ],
     "xbrltype": "centralIndexKeyItemType"
    },
    "dei_EntityCommonStockSharesOutstanding": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Indicate number of shares or other units outstanding of each of registrant's classes of capital or common stock or other ownership interests, if and as stated on cover of related periodic report. Where multiple classes or units exist define each class/interest by adding class of stock items such as Common Class A [Member], Common Class B [Member] or Partnership Interest [Member] onto the Instrument [Domain] of the Entity Listings, Instrument.",
        "label": "Entity Common Stock, Shares Outstanding"
       }
      }
     },
     "localname": "EntityCommonStockSharesOutstanding",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://microbotmedical.com/role/Cover"
     ],
     "xbrltype": "sharesItemType"
    },
    "dei_EntityCurrentReportingStatus": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Indicate 'Yes' or 'No' whether registrants (1) have filed all reports required to be filed by Section 13 or 15(d) of the Securities Exchange Act of 1934 during the preceding 12 months (or for such shorter period that registrants were required to file such reports), and (2) have been subject to such filing requirements for the past 90 days. This information should be based on the registrant's current or most recent filing containing the related disclosure.",
        "label": "Entity Current Reporting Status"
       }
      }
     },
     "localname": "EntityCurrentReportingStatus",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://microbotmedical.com/role/Cover"
     ],
     "xbrltype": "yesNoItemType"
    },
    "dei_EntityEmergingGrowthCompany": {
     "auth_ref": [
      "r2"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Indicate if registrant meets the emerging growth company criteria.",
        "label": "Entity Emerging Growth Company"
       }
      }
     },
     "localname": "EntityEmergingGrowthCompany",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://microbotmedical.com/role/Cover"
     ],
     "xbrltype": "booleanItemType"
    },
    "dei_EntityExTransitionPeriod": {
     "auth_ref": [
      "r19"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Indicate if an emerging growth company has elected not to use the extended transition period for complying with any new or revised financial accounting standards.",
        "label": "Elected Not To Use the Extended Transition Period"
       }
      }
     },
     "localname": "EntityExTransitionPeriod",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://microbotmedical.com/role/Cover"
     ],
     "xbrltype": "booleanItemType"
    },
    "dei_EntityFileNumber": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Commission file number. The field allows up to 17 characters. The prefix may contain 1-3 digits, the sequence number may contain 1-8 digits, the optional suffix may contain 1-4 characters, and the fields are separated with a hyphen.",
        "label": "Entity File Number"
       }
      }
     },
     "localname": "EntityFileNumber",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://microbotmedical.com/role/Cover"
     ],
     "xbrltype": "fileNumberItemType"
    },
    "dei_EntityFilerCategory": {
     "auth_ref": [
      "r2"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Indicate whether the registrant is one of the following: Large Accelerated Filer, Accelerated Filer, Non-accelerated Filer. Definitions of these categories are stated in Rule 12b-2 of the Exchange Act. This information should be based on the registrant's current or most recent filing containing the related disclosure.",
        "label": "Entity Filer Category"
       }
      }
     },
     "localname": "EntityFilerCategory",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://microbotmedical.com/role/Cover"
     ],
     "xbrltype": "filerCategoryItemType"
    },
    "dei_EntityIncorporationStateCountryCode": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Two-character EDGAR code representing the state or country of incorporation.",
        "label": "Entity Incorporation, State or Country Code"
       }
      }
     },
     "localname": "EntityIncorporationStateCountryCode",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://microbotmedical.com/role/Cover"
     ],
     "xbrltype": "edgarStateCountryItemType"
    },
    "dei_EntityInteractiveDataCurrent": {
     "auth_ref": [
      "r16"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Boolean flag that is true when the registrant has submitted electronically every Interactive Data File required to be submitted pursuant to Rule 405 of Regulation S-T during the preceding 12 months (or for such shorter period that the registrant was required to submit such files).",
        "label": "Entity Interactive Data Current"
       }
      }
     },
     "localname": "EntityInteractiveDataCurrent",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://microbotmedical.com/role/Cover"
     ],
     "xbrltype": "yesNoItemType"
    },
    "dei_EntityPrimarySicNumber": {
     "auth_ref": [
      "r14"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Primary Standard Industrial Classification (SIC) Number for the Entity.",
        "label": "Entity Primary SIC Number"
       }
      }
     },
     "localname": "EntityPrimarySicNumber",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://microbotmedical.com/role/Cover"
     ],
     "xbrltype": "sicNumberItemType"
    },
    "dei_EntityPublicFloat": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The aggregate market value of the voting and non-voting common equity held by non-affiliates computed by reference to the price at which the common equity was last sold, or the average bid and asked price of such common equity, as of the last business day of the registrant's most recently completed second fiscal quarter.",
        "label": "Entity Public Float"
       }
      }
     },
     "localname": "EntityPublicFloat",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://microbotmedical.com/role/Cover"
     ],
     "xbrltype": "monetaryItemType"
    },
    "dei_EntityRegistrantName": {
     "auth_ref": [
      "r2"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The exact name of the entity filing the report as specified in its charter, which is required by forms filed with the SEC.",
        "label": "Entity Registrant Name"
       }
      }
     },
     "localname": "EntityRegistrantName",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://microbotmedical.com/role/Cover"
     ],
     "xbrltype": "normalizedStringItemType"
    },
    "dei_EntityShellCompany": {
     "auth_ref": [
      "r2"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Boolean flag that is true when the registrant is a shell company as defined in Rule 12b-2 of the Exchange Act.",
        "label": "Entity Shell Company"
       }
      }
     },
     "localname": "EntityShellCompany",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://microbotmedical.com/role/Cover"
     ],
     "xbrltype": "booleanItemType"
    },
    "dei_EntitySmallBusiness": {
     "auth_ref": [
      "r2"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Indicates that the company is a Smaller Reporting Company (SRC).",
        "label": "Entity Small Business"
       }
      }
     },
     "localname": "EntitySmallBusiness",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://microbotmedical.com/role/Cover"
     ],
     "xbrltype": "booleanItemType"
    },
    "dei_EntityTaxIdentificationNumber": {
     "auth_ref": [
      "r2"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The Tax Identification Number (TIN), also known as an Employer Identification Number (EIN), is a unique 9-digit value assigned by the IRS.",
        "label": "Entity Tax Identification Number"
       }
      }
     },
     "localname": "EntityTaxIdentificationNumber",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://microbotmedical.com/role/Cover"
     ],
     "xbrltype": "employerIdItemType"
    },
    "dei_EntityVoluntaryFilers": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Indicate 'Yes' or 'No' if the registrant is not required to file reports pursuant to Section 13 or Section 15(d) of the Act.",
        "label": "Entity Voluntary Filers"
       }
      }
     },
     "localname": "EntityVoluntaryFilers",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://microbotmedical.com/role/Cover"
     ],
     "xbrltype": "yesNoItemType"
    },
    "dei_EntityWellKnownSeasonedIssuer": {
     "auth_ref": [
      "r17"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Indicate 'Yes' or 'No' if the registrant is a well-known seasoned issuer, as defined in Rule 405 of the Securities Act. Is used on Form Type: 10-K, 10-Q, 8-K, 20-F, 6-K, 10-K/A, 10-Q/A, 20-F/A, 6-K/A, N-CSR, N-Q, N-1A.",
        "label": "Entity Well-known Seasoned Issuer"
       }
      }
     },
     "localname": "EntityWellKnownSeasonedIssuer",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://microbotmedical.com/role/Cover"
     ],
     "xbrltype": "yesNoItemType"
    },
    "dei_Extension": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Extension number for local phone number.",
        "label": "Extension"
       }
      }
     },
     "localname": "Extension",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://microbotmedical.com/role/Cover"
     ],
     "xbrltype": "normalizedStringItemType"
    },
    "dei_LocalPhoneNumber": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Local phone number for entity.",
        "label": "Local Phone Number"
       }
      }
     },
     "localname": "LocalPhoneNumber",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://microbotmedical.com/role/Cover"
     ],
     "xbrltype": "normalizedStringItemType"
    },
    "dei_NoTradingSymbolFlag": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Boolean flag that is true only for a security having no trading symbol.",
        "label": "No Trading Symbol Flag"
       }
      }
     },
     "localname": "NoTradingSymbolFlag",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://microbotmedical.com/role/Cover"
     ],
     "xbrltype": "trueItemType"
    },
    "dei_OtherReportingStandardItemNumber": {
     "auth_ref": [
      "r13"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "\"Item 17\" or \"Item 18\" specified when the basis of accounting is neither US GAAP nor IFRS.",
        "label": "Other Reporting Standard Item Number"
       }
      }
     },
     "localname": "OtherReportingStandardItemNumber",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://microbotmedical.com/role/Cover"
     ],
     "xbrltype": "otherReportingStandardItemNumberItemType"
    },
    "dei_PreCommencementIssuerTenderOffer": {
     "auth_ref": [
      "r7"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act.",
        "label": "Pre-commencement Issuer Tender Offer"
       }
      }
     },
     "localname": "PreCommencementIssuerTenderOffer",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://microbotmedical.com/role/Cover"
     ],
     "xbrltype": "booleanItemType"
    },
    "dei_PreCommencementTenderOffer": {
     "auth_ref": [
      "r8"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act.",
        "label": "Pre-commencement Tender Offer"
       }
      }
     },
     "localname": "PreCommencementTenderOffer",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://microbotmedical.com/role/Cover"
     ],
     "xbrltype": "booleanItemType"
    },
    "dei_Security12bTitle": {
     "auth_ref": [
      "r1"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Title of a 12(b) registered security.",
        "label": "Title of 12(b) Security"
       }
      }
     },
     "localname": "Security12bTitle",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://microbotmedical.com/role/Cover"
     ],
     "xbrltype": "securityTitleItemType"
    },
    "dei_Security12gTitle": {
     "auth_ref": [
      "r5"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Title of a 12(g) registered security.",
        "label": "Title of 12(g) Security"
       }
      }
     },
     "localname": "Security12gTitle",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://microbotmedical.com/role/Cover"
     ],
     "xbrltype": "securityTitleItemType"
    },
    "dei_SecurityExchangeName": {
     "auth_ref": [
      "r4"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Name of the Exchange on which a security is registered.",
        "label": "Security Exchange Name"
       }
      }
     },
     "localname": "SecurityExchangeName",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://microbotmedical.com/role/Cover"
     ],
     "xbrltype": "edgarExchangeCodeItemType"
    },
    "dei_SecurityReportingObligation": {
     "auth_ref": [
      "r9"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "15(d), indicating whether the security has a reporting obligation under that section of the Exchange Act.",
        "label": "Security Reporting Obligation"
       }
      }
     },
     "localname": "SecurityReportingObligation",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://microbotmedical.com/role/Cover"
     ],
     "xbrltype": "securityReportingObligationItemType"
    },
    "dei_SolicitingMaterial": {
     "auth_ref": [
      "r10"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as soliciting material pursuant to Rule 14a-12 under the Exchange Act.",
        "label": "Soliciting Material"
       }
      }
     },
     "localname": "SolicitingMaterial",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://microbotmedical.com/role/Cover"
     ],
     "xbrltype": "booleanItemType"
    },
    "dei_TradingSymbol": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Trading symbol of an instrument as listed on an exchange.",
        "label": "Trading Symbol"
       }
      }
     },
     "localname": "TradingSymbol",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://microbotmedical.com/role/Cover"
     ],
     "xbrltype": "tradingSymbolItemType"
    },
    "dei_WrittenCommunications": {
     "auth_ref": [
      "r18"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as written communications pursuant to Rule 425 under the Securities Act.",
        "label": "Written Communications"
       }
      }
     },
     "localname": "WrittenCommunications",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://microbotmedical.com/role/Cover"
     ],
     "xbrltype": "booleanItemType"
    }
   },
   "unitCount": 3
  }
 },
 "std_ref": {
  "r0": {
   "Name": "Exchange Act",
   "Number": "240",
   "Publisher": "SEC",
   "Section": "12",
   "role": "http://www.xbrl.org/2003/role/presentationRef"
  },
  "r1": {
   "Name": "Exchange Act",
   "Number": "240",
   "Publisher": "SEC",
   "Section": "12",
   "Subsection": "b",
   "role": "http://www.xbrl.org/2003/role/presentationRef"
  },
  "r10": {
   "Name": "Exchange Act",
   "Number": "240",
   "Publisher": "SEC",
   "Section": "14a",
   "Subsection": "12",
   "role": "http://www.xbrl.org/2003/role/presentationRef"
  },
  "r11": {
   "Name": "Form 10-K",
   "Number": "249",
   "Publisher": "SEC",
   "Section": "310",
   "role": "http://www.xbrl.org/2003/role/presentationRef"
  },
  "r12": {
   "Name": "Form 10-Q",
   "Number": "240",
   "Publisher": "SEC",
   "Section": "308",
   "Subsection": "a",
   "role": "http://www.xbrl.org/2003/role/presentationRef"
  },
  "r13": {
   "Name": "Form 20-F",
   "Number": "249",
   "Publisher": "SEC",
   "Section": "220",
   "Subsection": "f",
   "role": "http://www.xbrl.org/2003/role/presentationRef"
  },
  "r14": {
   "Name": "Form 40-F",
   "Number": "249",
   "Publisher": "SEC",
   "Section": "240",
   "Subsection": "f",
   "role": "http://www.xbrl.org/2003/role/presentationRef"
  },
  "r15": {
   "Name": "Forms 10-K, 10-Q, 20-F",
   "Number": "240",
   "Publisher": "SEC",
   "Section": "13",
   "Subsection": "a-1",
   "role": "http://www.xbrl.org/2003/role/presentationRef"
  },
  "r16": {
   "Name": "Regulation S-T",
   "Number": "232",
   "Publisher": "SEC",
   "Section": "405",
   "role": "http://www.xbrl.org/2003/role/presentationRef"
  },
  "r17": {
   "Name": "Securities Act",
   "Number": "230",
   "Publisher": "SEC",
   "Section": "405",
   "role": "http://www.xbrl.org/2003/role/presentationRef"
  },
  "r18": {
   "Name": "Securities Act",
   "Number": "230",
   "Publisher": "SEC",
   "Section": "425",
   "role": "http://www.xbrl.org/2003/role/presentationRef"
  },
  "r19": {
   "Name": "Securities Act",
   "Number": "7A",
   "Publisher": "SEC",
   "Section": "B",
   "Subsection": "2",
   "role": "http://www.xbrl.org/2003/role/presentationRef"
  },
  "r2": {
   "Name": "Exchange Act",
   "Number": "240",
   "Publisher": "SEC",
   "Section": "12",
   "Subsection": "b-2",
   "role": "http://www.xbrl.org/2003/role/presentationRef"
  },
  "r3": {
   "Name": "Exchange Act",
   "Number": "240",
   "Publisher": "SEC",
   "Section": "12",
   "Subsection": "b-23",
   "role": "http://www.xbrl.org/2003/role/presentationRef"
  },
  "r4": {
   "Name": "Exchange Act",
   "Number": "240",
   "Publisher": "SEC",
   "Section": "12",
   "Subsection": "d1-1",
   "role": "http://www.xbrl.org/2003/role/presentationRef"
  },
  "r5": {
   "Name": "Exchange Act",
   "Number": "240",
   "Publisher": "SEC",
   "Section": "12",
   "Subsection": "g",
   "role": "http://www.xbrl.org/2003/role/presentationRef"
  },
  "r6": {
   "Name": "Exchange Act",
   "Number": "240",
   "Publisher": "SEC",
   "Section": "12, 13, 15d",
   "role": "http://www.xbrl.org/2003/role/presentationRef"
  },
  "r7": {
   "Name": "Exchange Act",
   "Number": "240",
   "Publisher": "SEC",
   "Section": "13e",
   "Subsection": "4c",
   "role": "http://www.xbrl.org/2003/role/presentationRef"
  },
  "r8": {
   "Name": "Exchange Act",
   "Number": "240",
   "Publisher": "SEC",
   "Section": "14d",
   "Subsection": "2b",
   "role": "http://www.xbrl.org/2003/role/presentationRef"
  },
  "r9": {
   "Name": "Exchange Act",
   "Number": "240",
   "Publisher": "SEC",
   "Section": "15",
   "Subsection": "d",
   "role": "http://www.xbrl.org/2003/role/presentationRef"
  }
 },
 "version": "2.2"
}
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>ZIP
<SEQUENCE>20
<FILENAME>0001493152-23-018456-xbrl.zip
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
begin 644 0001493152-23-018456-xbrl.zip
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M/@TNSMO%0NM3MW,*_Q/\TQKT!N?==JMJ_H=OJ\G7K9.KTZ^D/_AZWGU?<L-
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M;)K_G)&A+VPF"I;O.#0(0:CD**<*5;5!_^D#W# AD6XF1@.#Y^*R5VW0>K;
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M2?VT YC3) $8@S1T'P(#! ,5QT1I\/DB5S&Z%#GQV+K(B[+#X',CHR1K!D_
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M[C#$VQ7<X5"_VM<ZU 03KZ0YQ&J1="&;6UT:K/A$1@?#Y@:,8IW9EG#(%C[
M46445H],.H3UH%\BU&NF?]@GDTJF,J%DKI1[HNHY+Z*U33Y])@K7XNQ"[#U;
MVWA1C8\QWG?V=>BI"_4Z.AT, ')F1FFC$&"QXCD=@/[<)MCH6C^M!FZ!.33)
MHWF?1SU_;9VUN<30F(/^ZV@6;66N=?<T_SW/.PLPB*+Z!0ZLE>N71Y>@1L^K
ME5JY=$9J%^7$N^-%&*^M:I]JH&&18BA]Q)!2A$HB;::AAU8G' ;5D004$ @C
ML<*J-WI^.K1I,.C-,."YIL+YJ9CZ;5-=#W[/C?^8\VCH$](LPZ"V!("";Y[7
M]= 1\W?08\+! %Y +Z!TX,,]=/1G YS-_/,*O#DI2\HA65(S-4N ;E0!]H8#
MFJ7L!7G+ECY#M%P6[D^L\G7J_G-^$=H/\P PP. P6U@]G$%A]?<$.&/%"C/H
M/2C.IP@?1U_ V+W\T$U,H85 _38<5PUQW#$W& Q/DXEH]KHKU+[^J@_N'KYK
M"]-<HSY5""V>+NSETVM>64)>R89XY8;V:WY\4U,S_S'&^=6L]7Z>G_9+G^X6
MQC@S (@5"[EX-I7?2V>F0N0SV C^$<NB@8 \JV%FH.FEE(%'"DL0"U;[@OR$
MQ;[4N?)U3!E9BF@K@S]Z.! C/JX@)RW+/Q4)?XWT6BG.+EO=+I=R]7D8U;.'
MDR=>U^R[ H.Z5:LW/$)4N[9A#9A8<2X.&PH^/UN)2&8>60-)M2@NKOC*?S5P
MB[!72R%[M:3K@DGI?YQQDZ6C;=72?T\,SCYKSEYZ8;9J1.>Q8F9G<Z/.-,$4
M4Y(K*NY(1?#>K)7R]I1_//,;##/1&![9J:NKK]^-=-EX00PSL>(73+!+I_;>
MH]_Q2=Q8AJ^7XL:Z-Z-'RCS2\P^E7C-WE5OT2(VZCA4_<;/=H=U9?#<=_8]$
M1EG[E^)*6#VP>&=XJ,[:YMU.<[=T9CQ_)3BWARH:0(S32$FUCBN9X\@9V$]-
MNG04[E<6 &'\X/9LWUSCZ,=EZS[[[2?GBQ[+4.^Q8BJ3RKV_N!/:-3X]5-CQ
M2L @<YL:I-IGFNN 8"67+; !F/Q MH!8!*GU[AS]JX$;#/8HY/7O?^UETOD#
M&':'&<SN6"8CIEJM;./:VW Q?D$H*%J8:#J;CC/G_"F-,K$$Q69/8MOHFI]W
MO]_]<!<AD,?[BQ6W\GOI#T^50GL^R&>61HTK1/DQ_UOY6NHGW[5VY7-[ 6!/
M]ADK[N5WXMG=U),<;BO%ARL^Q[:.0=4RL;EQH:*G@GB_B2]G87JU2%FE[.BD
M@3J5G%'I^!D?:]'Z"KC]="4L; >+1*[<8=J=EYM%;3"K;,$Q<Z=I]4F3&=8]
M#CJ^1%X@>_%3TN(&"E@N0=HZS-2!&1R+2-YU#8>:S'*E,2 25CFR-5 U_0I6
M$W#P%C^6U^18<-Z%=H#QJ#D(7K8L WK'BFCK<72^R?TE&@/_(3?1V0"%$CO<
M7(7 _?)%YU.)S()I.ROS[*O@#K TNGM=TW<?R6@=ZY2R\L<G?OJK]GP=.YYY
MUK0L@U%3;<$<U[Z1("%W%/*YW,%,#;R0^.,+2QX?-2#7.&X>O+:?*XNB!?<"
MD5QFQQ,29"*+%)-'M])Y4CZN$QB<!!3\L,3AOF5T=K_X2$_#NJJC,LMGU[ ,
MK@'#FNUST*Z@8HUHL<*-^M[I53:S8^HO*E:FX5D-F3+""W2XA]A0EGA0!P(E
MG:/Q=&9,IH32T8<2)9=*>"770F7)AOK]"I5C7ZA<"89V 1Z4H#9)H3$N+ENM
M67X!_5/3N-8ROVC[^7NSGB)<9L.U&D(&\(MK8P@^S8))Y_1X9JOYX6DBQRN[
M%CI+-O3O5^CDHX5.34J7B=^*GB\G_53UO//E:_Y51<\4=.]: &59/+>E/4T
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MW^2._EQNOL8KDHZ05 H^P':=-NHJ@R:NS=X1GK#XDK[/M1GMR;[X[O#\?VA
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M]P_))8T'(5+I_ !BV+3C48H"A*/IK \-H?8)QE6213A57J[$MJRC>1:M:T!
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MMG/'5)* \+#YZL@@PY'6>F%AL<%I^GF;)91D\$1DJ-RR8+789*$A"8@%FR^
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M]0K02CXC5E:!?I.5H*(6V^^7US==BT]BL]XD_EKAC(@M_P502P,$%     @
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M3^&;(D!Q:'Q0WR@$QE 1IHOND:Y;>\"]K;;XQOUR;V2U1_X'4$L! A0#%
M  @ R4.V5DQQ4(LS"P  %%P   H              ( !     &5X,3 M,2YH
M=&U02P$"% ,4    " #)0[963[*3'T<+  !%70  "@              @ %;
M"P  97@Q,"TR+FAT;5!+ 0(4 Q0    ( ,E#ME8'G#4N1@L  *1;   *
M          "  <H6  !E>#$P+3,N:'1M4$L! A0#%     @ R4.V5L5D_B,5
M"@  AE    H              ( !."(  &5X,3 M-"YH=&U02P$"% ,4
M" #)0[96/1K]8Z<+  !6,@  "@              @ %U+   97@Y.2TQ+FAT
M;5!+ 0(4 Q0    ( ,E#ME9%8*Z$&A@  "C(   +              "  40X
M  !F;W)M."UK+FAT;5!+ 0(4 Q0    ( ,E#ME;L?LV<50,  ,X,   1
M          "  8=0  !M8F]T+3(P,C,P-3$X+GAS9%!+ 0(4 Q0    ( ,E#
MME8,KO!L_@H  ("&   5              "  0M4  !M8F]T+3(P,C,P-3$X
M7VQA8BYX;6Q02P$"% ,4    " #)0[96_+JU-UT'  #C5P  %0
M    @ $\7P  ;6)O="TR,#(S,#4Q.%]P<F4N>&UL4$L%!@     )  D %@(
' ,QF      $!

end
</TEXT>
</DOCUMENT>
</SEC-DOCUMENT>
